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ABSTRACT 
 
 
In rabbits, an acute inflammatory reaction induced by the injection of turpentine causes a 
decrease in cytochrome P450 (CYP) isoforms activity and expression. Chondroitin sulfate (CS) is a 
Symptomatic Slow Acting Drug for OsteoArthritis (SYSADOA) that elicits anti-inflammatory 
effects. Since patients take CS over long periods, it was of interest to assess whether CS modulates 
the activity of cytochrome P450 isoforms. In order to determine the effect of CS on the cytochrome 
P450, CS was administered in vivo to two animal models, e.g. chronic intake of CS in control rabbits, 
and chronic intake of CS in rabbits with a CYP down-regulated by an inflammatory reaction (IR).  
We used six groups of five rabbits: three to assess the effect of CS on cytochrome P450, one without 
CS and two receiving orally about 20 mg/kg/day CS for 20 and 30 days; and the remaining three 
groups of rabbits received turpentine s.c. to generate an aseptic IR (AIR) 48 h before their sacrifice, 
e.g. days -2, 18 and 28, while exposed to CS for 0, 20 or 30 days, respectively.  
In order to verify the presence of inflammation we measured the seromucoids in serum of 
rabbits with an AIR. Another marker of inflammation, e.g. nitric oxyde  (NO.) production, was 
assessed in control hepatocytes (Hcont) and in hepatocytes from rabbits with an AIR (Hinfla). In 
addition, the effect of CS on the nuclear translocation of NF-κB was studied by fluorescence in 
hepatocytes. Finally, in hepatocytes (both Hcont and Hinfla) the CYP3A6, CYP1A2 and NADPH 
P450 reductase (NADPH) activity, expression and mRNA were measured. In vitro, the effect of 
different concentrations of CS, 4S-, 6S- and 4,6S-sulfated disaccharides of CS on the cytochrome 
P450 was documented. 
Compared with control rabbits, 20 and 30 days CS did not affect the activity of CYP3A6 and 
CYP1A2. The AIR increased seromucoids from 8.4±1.6 mg/dl in controls to 95.1±5.7 (p<0.05), as 
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well as the nuclear translocation of NF-κB, and nitric oxide concentrations. The AIR reduced 
CYP3A6 activity by 62% and CYP1A2 activity by 54%, decrease associated to a reduction in protein 
expression and in mRNA, e.g. pre-transcriptional down-regulation.  
The nuclear translocation of NF-κB was prevented by the administration of CS to rabbits with an 
AIR, moreover CS impeded the increase of the concentrations of nitric oxide; however CS did not 
prevent the increase in seromucoids. CS did not prevent the down-regulation of CYP1A2 produced 
by the inflammatory reaction. 
CS prevented the time-dependent down-regulation of CYP3A6 in control rabbits and in rabbits 
with an inflammatory reaction. In this last group, CS restored the amounts of CYP3A6 protein to 
levels observed in control rabbits, however this increase was independent of the mRNA that 
remained very depressed. It is noteworthy that even if CS increased CYP3A6 protein, its activity was 
not recovered. CS did not affect NADPH activity or expression.  
Finally, in vitro, CS, 4S-, 6S and 4,6S-sulfated disaccharides of CS did not change the activity 
and expression of the two isoforms of CYP, and of NADPH. 
It is concluded that CS does not affect the activity or expression of CYP1A2, nor prevents 
CYP1A2 AIR-induced down-regulation. However, CS prevents the down-regulation of CYP3A6 
time dependently and following the AIR but does not prevent the decrease of catalytic activity. 
 
Keywords: cytochrome P450, NADPH-reductase, inflammation, chondroitin sulfate, osteoarthritis 
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RESUME  
 
Le CS fait partie de la famille des SYSADOA (SYmptomatic Slow Acting Drugs for 
OsteoArthritis) et est utilisé par les patients avec de l’ostéoarthrose de façon chronique pour ses 
propriétés anti-inflammatoires. Étant donné que ces patients reçoivent d’autres médicaments, il 
était intéressant de documenter les effets du CS sur le cytochrome P450 et la NADPH-
réductase (NADPH).  
Pour cette étude, deux modèles ont été utilisés: des lapins témoins (LT) et des lapins avec une 
réaction inflammatoire (LRI) afin de diminuer l’activité et l’expression du CYP. Six groupes 
contenant chacun cinq lapins ont été utilisés: un groupe sans CS et deux groupes qui ont pris 
oralement dans l’eau approximativement 20.5 mg/kg/jour de CS pendant 20 et 30 jours; les lapins des 
trois groupes restants ont pris du CS comme décrit plus haut, mais ont reçu 5 ml sous-cutanées de 
térébenthine afin de produire une réaction inflammatoire aseptique (RIA) deux jours avant leur 
sacrifice, c’est-à-dire aux jours -2, 18 et 28. Les hépatocytes ont été isolés pour évaluer l’activité et 
l’expression du CYP3A6, CYP1A2 et NADPH et aussi le ARNm de ces protéines.  In vitro, nous 
avons étudié l’effet de différentes concentrations de CS-disaccharides sulfatés, 4S, 6S, et 4,6S de CS, 
sur l’activité et l’expression du CYP1A2 et du CYP3A6. Pour documenter la présence de la réaction 
inflammatoire, nous avons mesure les mucoprotéines, dans le sérum des lapins avec une réaction 
inflammatoire. Aussi nous avons mesuré la présence de l’oxide nitrique (NO) chez les hépatocytes de 
lapins contrôles et chez les hépatocytes des lapins avec une réaction inflammatoire. La translocation 
nucléaire du NF-κB a été etudiée par fluorescence chez les hépatocytes. 
Par comparaison aux lapins témoins, l’administration du CS pendant 20 et 30 jours n’affecte pas 
l’activité du CYP3A6 et du CYP1A2.  La RIA a augmenté les mucoprotéines à 95,1±5,7 vs 8,4±1,6 
mg/dl dans les lapins témoins (p<0,05). La RIA a diminué l’activité du CYP3A6 de 62% et l’activité 
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du CYP 1A2 de 54%.   Le CS n’empêché pas la diminution du CYP1A2 produite par la RIA. Par 
ailleurs, le CS n’affecte pas l’activité ni l’expression de la NADPH.  
La translocation nucléaire de NF-κB a été empêche par l’administration chronique de CS aux 
lapins avec RIA; en plus, la concentration de l’oxide nitrique n’a pas démontré une augmentation en 
présence de CS; par contre, CS n’empêche pas l’augmentation des séromucoïdes.  
Au contraire, CS affecte la diminution du CYP3A6 en fonction de temps et secondaire à la RIA. 
Dans ce group, CS a rétabli le niveau des protéines du CYP3A6 observé dans le group de lapins 
témoins. Pourtant cette croissance été independante de mRNA qui garde un niveau trés bas. Le plus 
remarcable a été la manière dont CS a augmenté la protéine du CYP3A6, sans avoir rétabli l’activité 
de cet isoforme.  Finalement, in vitro, CS et ses trois disaccharides sulfatés (4S, 6S et 4,6S) 
n’affectent ni l’activité ni l’expression de CYP1A2, CYP3A6 et de la NADPH. 
En conclusion, l’administration chronique de CS n’affecte pas l’activité ni l’expression du 
CYP1A2, ou la diminution du CYP1A2 produite par la réaction inflammatoire. Le CS n’affecte pas 
l’activité ni l’expression du NADPH. Cependant, CS empêche la diminution du CYP3A6 en fonction 
de temps et secondaire à la RIA. 
 
Mots-clés : cytochrome P450, NADPH-réductase, inflammation, chondroitin sulfate, ostéoarthrite. 
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PART I: CYTOCHROME P450s 
 
 
The purpose of this chapter is to review the main enzymes of the human cytochrome P450 
(CYP) family and to understand its pivotal role in the metabolism of drugs.  
 
1.1 The metabolism 
 
 
The body is equipped with several mechanisms to ensure that the xenobiotics are effectively 
eliminated from the body. The small and non-polar molecules have a great affinity for membranes 
rendering them difficult to be eliminated. The role of metabolism is to promote excretion of these 
molecules by oxidizing a lipophilic and non-polar product in to a hydrophilic and polar one. 
Xenobiotic biotransformation is the principal mechanism for maintaining homeostasis during 
exposure of organisms to small foreign molecules and occurs predominantly in the liver, although 
biotransformation also occurs in the intestine, kidneys, lungs, placenta, nasal mucosa, and skin. 
Generally, the reactions catalyzed by drug-metabolizing enzymes are divided into two groups, 
phase I and phase II reactions. Phase I reactions introduce a functional group that increases 
hydrophilicity and they can lead to either activation or inactivation of the drug. Phase I reactions are 
mediated by the cytochrome P450, flavin-containing monooxygenase, xanthine oxidase, 
prostaglandin H synthase, amine oxidase, alcohol dehydrogenase, aldehyde dehydrogenase, epoxide 
hydrolase, and esterase. Among of all these enzymes, the cytochrome P450s are by far the most 
common and the most important. Phase II reactions include glucuronidation, sulfation, methylation, 
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acetylation, glutathione conjugation, and amino acid conjugation. In general, these reactions, with the 
exception of methylation and acetylation, result in a large increase in xenobiotic hydrophilicity.  
It is generally recognized that the expression of drug-metabolizing enzymes may be altered in 
response to development, aging, gender, genetic factors, nutrition, pregnancy, and pathophysiological 
conditions such as diabetes, long-term alcohol consumption, inflammation, and protein-calorie 
malnutrition. 
 
1.2 Taxonomy of the cytochromes p450 
 
The cytochrome P450 superfamily of enzymes comprises over 7700 known members, or distinct 
CYP gene sequences, across all organisms (http://drnelson.utmem.edu/CytochromeP450.html for 
latest count). The human genome encodes 57 different forms of CYP proteins, called isoforms or 
isoenzymes (Lewis, 2004; Guengerich, 2005). Of these, 15 or more are associated with drug and 
other xenobiotic metabolism in humans, including CYP1A1, CYP1A2, CYP1B1, CYP2A6, 
CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, 
CYP3A5, and CYP3A7 (Guengerich, 2003; Lewis, 2004). The nomenclature for CYP isoforms is 
derived from amino acid sequence similarity determined through gene sequencing. Usually, amino 
acid sequences with greater than 40% similarity are placed in the same family, designated by a 
number (e.g., CYP1), while those with greater than 55% similarity are grouped in the same 
subfamiliy, designated by a letter (e.g., CYP1A) (Danielson, 2002).  
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1.3. Structure and mechanism of action 
 
The overall global structure of CYP enzymes is globular, composed of alpha and beta 
substructures, with several of these secondary motifs roughly coplanar to the prosthetic heme group 
(Danielson, 2002) (see Protein Data Bank for structures of CYPs: http://www.rcsb.org) (Figure 1). In 
eukaryote, the vast majority of these proteins are bound to the endoplasmic reticulum membrane.  
 
 
                   
 
 
 
 
 
 
 
Figure 1  Secondary and tertiary structure of cytochrome P450. 
 Source: http://www.rcsb.org 
 
Substrate reactivity can be altered by as little as a single amino acid difference, resulting in 
significant changes in substrate affinity and reaction regioselectivity and velocity (Danielson, 2002). 
The effects of such alterations may be observed in individuals possessing heritable genetic point 
mutations, or single nucleotide polymorphisms (SNPs), in their CYP genes, which may lead to 
reduced activity of the relevant isozyme (Parkinson, 2001). Interindividual allelic variations of this 
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nature can have undesirable pharmacological consequences, such as low blood clearance of a drug 
and exacerbation of toxic effects in poor metabolizers (Parkinson, 2001).  
As a consequence, the CYP isoforms demonstrate differential affinity toward a myriad of 
potential substrates, as well as chemo- and region-selectivity toward reaction sites within these 
molecules. Active sites differences are found in substrate recognition sites (i.e., groups of amino 
acids in the active site that may determine reaction products by orienting the molecule via 
complementary chemical interactions) (Danielson, 2002). 
 
1.4. General Properties and Mechanism of Action 
 
The CYPs are moderately sized proteins having molecular weights that fall within the range of 
48 to 53 kDa. The catalytic component of CYP is a heme cofactor, and the enzyme utilizes the redox 
chemistry of the Fe3+/Fe2+ couple to activate molecular oxygen to oxidize and chemically modify 
drug molecules. The complete functional system also involves a second enzyme, cytochrome P450 
reductase. Cytochrome P450 reductase is a 190-kDa protein that has both flavin adenine dinucleotide 
(FAD) and flavin adenine mononucleotide (FMN) as cofactors that serve to sequentially transfer 
reducing equivalents from reduced nicotine adenine dinucleotide phosphate (NADPH) to cytochrome 
P450. NADPH cannot reduce cytochrome P450 directly; the heme Fe3+ of CYP can only accept 
electrons in discrete single electron steps, whereas reduction by a hydride (H–) ion from NADPH is a 
two-electron process. However, either the FMN or FAD cofactors of cytochrome P450 reductase can 
undergo a direct two-electron H– reduction by NADPH and then transfer the electrons to CYP in 
single one-electron steps. O2 is split into two oxygen atoms but only one atom is utilized in oxidizing 
the substrate (RH) while the second atom is reduced by two electrons to form water, in conformity 
with the following equation:  
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CYP + O2 + RH + 2e− + 2H+ → CYP + ROH + H2O 
 
The cytochrome P450 catalytic cycle (1) is shown in greater detail in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Catalytic cycle of cytochrome P450. 
Source: http://www.tcm.phy.cam.ac.uk/~mds21 
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Step 1.  
The substrate, RH, associates with the active site of the enzyme and perturbs the spin-state 
equilibrium. Water is ejected from the active site and the electronic configuration shifts to favor the 
high-spin form in which pentacoordinated heme Fe3+ becomes the dominant form-binding substrate. 
In this coordination state, Fe3+ is puckered out and above the plane in the direction of the sixth ligand 
site. The change in spin state alters the redox potential of the system so that the substrate-bound 
enzyme is now more easily reduced. 
 
Step 2.  
NADPH-dependent P450 reductase transfers an electron to heme Fe3+ to reduce it to heme Fe2+. 
 
Step 3.  
O2 binds to Fe2+, but can also dissociate. If it dissociates, the enzyme reverts to the heme Fe3+ resting 
state and generates superoxide radical anion in the process. 
 
Step 4.  
A second electron, via P450-reductase or in some instances cytochrome b5, is added to the system 
generating a heme-bound peroxide dianion formally equivalent to FeO2+. 
 
Step 5.  
H+ adds to the system generating a heme-bound hydroperoxide anion complex formally equivalent to 
heme FeO2H2+. 
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Step 6.  
A second H+ is added. If H+ adds to the inner oxygen of heme, FeO2H2+ decoupling occurs, H2O2 is 
released, and the enzyme reverts to the heme Fe3+ form. 
 
Step 7.  
If the second H+ adds to the outer oxygen of heme FeO2H2+, water is formed and released. Residual 
heme FeO3+ bears an oxygen atom (oxene) complexed to heme Fe3+, a species considered to be 
analogous to compound 1, the reactive intermediate of the peroxidases. Decoupling can again occur 
via a two-electron reduction of FeO3+ plus the addition of two protons. This generates a molecule of 
water and the heme Fe3+ resting state of the enzyme. The degree to which this process occurs depends 
on the relative rates of heme FeO3+ reduction versus oxygen atom transfer to the substrate as outlined 
in the next step (2). 
 
Step 8.  
An oxygen atom is transferred from heme FeO3+ to the substrate forming the oxidized product, 
thereafter the product is released, and the enzyme reverts to its heme Fe3+ resting state. 
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1.5. Reactions catalyzed by cytochrome p450 
 
 
The cytochrome P450 enzyme superfamily, one of the most important drug-metabolizing 
enzyme systems in humans, is responsible for the oxidative metabolism of a large number of 
endogenous compounds and xenobiotics (Nebert, 2002). Few enzymes are more striking in both 
versatility and in sheer number of substrates than the cytochrome P450 enzyme system. CYP 
detoxify harmful xenobiotics or, in some instance, bioactivate them to reactive species, through 
biotransformation (Ortiz de Montellano, 2005; Parkinson, 2001). The ubiquitous presence of CYP 
enzymes, paired with their broad substrate selectivity, suggest that the biotransformations catalyzed 
by these enzymes were essential to an organism’s ability to adapt to its environment. CYP enzymes 
catalyze the majority (>80%) of drug-related metabolism in humans (Guengerich, 2005), as well as 
the biosynthesis or catabolism of numerous endogenous substrates such as steroid hormones, 
eicosanoids, vitamine D, etc (Lewis, 2001). Common CYP mediated reactions are: alkyl 
hydroxylation, oxidation, dealkylation, epoxidation, and dehydrogenation.  
 
 
1.6. Variability and Polymorphism  
 
The area of pharmacogenetics (now also known as — or expanded to —"pharmacogenomics") 
was facilitated by the identification of the CYP enzymes involved in the drug metabolism 
phenotypes, and particularly by the development of molecular biology, which allows the precise 
characterization of genetic differences between individuals. The majority of the allelic differences are 
single nucleotide polymorphisms (SNPs), or single base changes. As anticipated from previous 
knowledge of pharmacoethnicity, many of these SNPs and polymorphisms show racial linkage. A 
24 
 
polymorphism is generally defined as a 1% frequency of an allelic variant in a population; below this 
frequency, the terms "rare genetic trait" or "rare allele" are applied or, in the case of a very 
detrimental allele, a mutant or "inborn error of metabolism.” A nomenclature system has been set up 
for CYP alleles (using the suffixes *1, *2, *3... and is maintained by Oscarson at 
http://www.imm.ki.se/Cypalleles/  (Ortiz de Montellano, 2005). 
The first characterization of a monogenic variability in a human drug-metabolizing CYP was 
the work of Smith with debrisoquine (Mahgoub, 1997) to which was added the work of Dengler 
and Eichelbaum on sparteine (Eichelbaum et al., 1979). This polymorphism was first described in 
the context of extensive metabolizers (EMs) and poor metabolizers (PMs). The debrisoquine 
polymorphism is now understood in terms of CYP2D6 and has been a prototype for research in 
this area.  
Though CYP2D6 and CYP2C19 are often mentioned as displaying polymorphism, allelic 
mutants have been described in most human CYP isozymes involved in exogenous biotransformation 
(Smith et al., 1998). The study of CYP polymorphisms has been instrumental in discovering the 
substrate affinities of several isozymes; for example, the metabolism of S-mephenytoin was 
originally thought to be catalyzed exclusively by CYP2C9. However, kinetic studies of several 
variants of CYP2C9, derived from SNPs, showed that its relative contribution to S-mephenytoin 
biotransformation is negligible, being predominantly metabolized by CYP2C19 (Smith et al., 1998). 
It should be pointed out that several of the CYPs can be down-regulated by cytokines, and the 
result has practical significance in the impairment of drug metabolism in individuals with colds or 
flu, or who have received vaccinations (Renton and Knickle, 1990). 
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1.7. Human CYP Enzymes 
 
 
The following section briefly outlines important aspects of each family of human CYP. Members 
of three families of cytochrome P450, CYP1, CYP2, and CYP3 dominate human drug metabolism, 
and the primary property that distinguishes one CYP from another is the difference in the spectrum of 
activity displayed by each individual isoform in their ability to discriminate between substrates.  
Further details, on each of the 57 human CYPs, can be found elsewhere (Crivori and Poggesi, 2006; 
Danielson, 2002; Ekins et al., 2001; Lewis, 2001; Ortiz de Montellano, 2005; Parkinson, 2001). 
 
1.7.1. CYP1 family 
 
The CYP1A subfamily contains the two members, CYP1A1 and CYP1A2, which are involved in 
drug metabolism and have sparked considerable interest because they also seem to be associated with 
the metabolic activation of pro-carcinogens to mutagenic species. 
 
• CYP1A1 
In humans, of the two members, CYP1A2 is the major player while CYP1A1 is a relatively 
minor extrahepatic isoform associated with the oxidation of polycyclic aromatic hydrocarbons like 
benzo[a]pyrene. Similarly, in test rodent species CYP1A1 is responsible for the generation of toxic 
intermediates and carcinogenic metabolites (Miners and Mckinnon, 2000).  
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• CYP1A2 
CYP1A2 has been implicated in the activation of procarcinogenic species such as aflatoxin B1, 
2-acetylaminofluorene, and other arylamines. It tends to favour aromatic substrates, both heterocyclic 
aromatic substrates like caffeine and aromatic substrates like phenacetin (Miners and McKinnon, 
2000). In the case of caffeine, CYP1A2 is the major isoform catalyzing the N-demethylation at the 
three N-methyl sites. In this regard, the 3-N-demethylation of caffeine to generate paraxanthine can 
serve as a particularly good in vivo indicator of the presence and activity of CYP1A2. Differences in 
CYP1A2 activity have clinical relevance. For instance, low CYP1A2 activity toward phenacetin 
favours a potentially toxic secondary pathway, deacetylation followed by quinoneimine formation 
and methemoglobinemia (Fischback and Lenk, 1985). High levels of CYP1A2 activity have also 
been associated with ineffectiveness of theophylline therapy (for asthma) (Kappas et al., 1978). 
Another concern is the co-carcinogenic effect. In this regard, there is some epidemiological evidence 
that high CYP1A2 activity (measured as in vivo caffeine metabolism) is associated with enhanced 
risk of colon cancer, although the effect was not seen in the absence of high N-acetyltransferase 
activity and high consumption of charbroiled meat (Lang et al., 1994). Some drug interactions at the 
CYP1A2 level have been reported. 
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1.7.2. CYP2 family 
 
 
The CYP2 family contains isoforms from at least five subfamilies, 2A, 2B, 2C, 2D, and 2E, 
which contribute significantly to drug metabolism.  
 
• CYP2A6 
The 7-hydroxylation of coumarin (Pelkonen et al., 2000) and the initial carbon hydroxylation of 
the α-carbon to the pyrrolidine nitrogen of nicotine, which upon further oxidation by aldehyde 
oxidase (AO) yields cotinine, are the defining metabolic activities associated with CYP2A6. 
CYP2A6 is also responsible for the stereospecific 3’-hydroxylation of cotinine to form trans-3’-
hydroxycotinine (Nakajima et al., 1996), a major metabolite of nicotine in the human. CYP2A6 is 
polymorphic and its activity has a significant effect on smoking behaviour. People with reduced or 
deficient CYP2A6 levels demonstrate a significantly reduced dependency upon nicotine (Tyndale 
and Sellers, 2002). While CYP2A6 is the primary CYP responsible for nicotine metabolism, only a 
few other substrates have thus far been identified where CYP2A6 serves a similar role (Le Gal, 
2003). The few that have been identified suggest that the active site of CYP2A6 favours small 
aromatic or heteroaromatic substrates, alkoxy ethers, and N-nitrosoalkylamines that are neutral or 
basic in character.     
CYP2A6 expression has been reported to be induced during infection by (carcinogenic) liver 
flukes (Satarug et al., 1996) and down-regulated during infection by hepatitis A virus (Pasanen et 
al., 1997).     
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• CYP2B6     
While generally accounting for significantly less than 1% of the total CYP present in human 
liver, CYP2B6 is also found in extrahepatic tissue, including brain, and it has been established as a 
major catalyst for the oxidation of several important drugs in current clinical use. For example, 
CYP2B6 catalyzes the 4-hydroxylation and the N-decholorethylation of the anticancer agents’ 
cyclophosphamide and ifosfamide (Chang et al., 1993), respectively, the 4-hydroxylation of the 
anaesthetic agent propofol (Oda et al., 2001), and the methyl group hydroxylation of the 
antidepressant and antismoking agent bupropion (Hesse et al., 2000). The O-deethylation of 7-
ethoxy-4-trifluoromethylcoumarin has been the favoured substrate to probe for CYP2B6 activity 
(Yuan et al., 2002), but recent evidence indicates that it is not as selective for CYP2B6 as one would 
hope because both CYP1A2 and CYP2E1 also catalyze this reaction. A much better indicator of 
CYP2B6 activity appears to be the N-demethylation of (S)-mephenytoin, particularly at higher 
concentrations of (S)-mephenytoin. 
 
• CYP2C9 
CYP2C9 is the most abundant isoform of the CYP2C subfamily (CYP2C8, CYP2C9, CYP2C18, 
and CYP2C19) and one of the most extensively characterized of all the human CYPs. The active site 
has been explored with a variety of substrates, and computer-derived homology models that predict 
substrate affinity have been developed. The enzyme displays a distinct preference for acidic 
substrates with the defining substrates being warfarin, tolbutamide, and the nonsteroidal anti-
inflammatory drugs (NSAIDS). Typical examples of the latter are flurbiprofen and diclofenac. In the 
case of warfarin, CYP2C9 stereoselectively catalyzes the 7-hydroxylation and 6-hydroxylation of 
(S)-warfarin to generate both (S)-7-hydroxywarfarin and (S)-6-hydroxywarfarin in a ratio of 3:1. 
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Together the two biologically inactive metabolites account for more than 80% of the clearance of (S)-
warfarin from the body (Black et al., 1996). Since (S)-warfarin is responsible for most of the drugs 
anticoagulant activity [(S)-warfarin is five to eight times more potent an anticoagulant than (R)-
warfarin], CYP2C9 effectively controls the level of anticoagulation by controlling the in vivo 
concentration of (S)-warfarin, a drug with a narrow therapeutic index. As a consequence, interference 
with CYP2C9 activity could be expected to have a major impact on anticoagulant response. Thus, if a 
second drug, in addition to warfarin, were present in vivo, and if the second drug were either a 
substrate and/or inhibitor of CYP2C9, a serious drug interaction could result. This indeed seems to be 
the case as a number of warfarin drug interactions have been shown to be caused by a second drug 
inhibiting CYP2C9 (Rettie et al., 1992), and the metabolic inactivation of (S)-warfarin as a direct 
consequence. In this regard, it is informative to note that while (R)-warfarin is not a substrate of 
CYP2C9, it is a reasonably potent inhibitor (Ki = 8 µM) of the enzyme, and does affect the 
elimination rate of (S)-warfarin (Km = 4 µM) when the drug is administered as a racemate, its normal 
mode of administration (Kunze et al., 1991). Therefore, while the two enantiomers of the drug have 
comparable affinities for the enzyme, one enantiomer is a substrate while the other is an inhibitor.  
Hydroxylation of the benzylic methyl group of tolbutamide, the preferred site of oxidative attack 
by CYP2C9 (Veronese et al., 1991), generates hydroxytolbutamide. Hydroxytolbutamide is rapidly 
oxidized by other enzymes, presumably aldehyde oxidase and/or alcohol dehydrogenase (ALD), to 
form the major isolated metabolite, the benzoic acid analog. 
The major CYP2C9-catalyzed transformation of (S)-flurbiprofen is formation of (S)-4`-
hydroxyflurbiprofen (Tracy et al., 1995) and that of diclofenac is formation of 4`-hydroxydiclofenac 
(Leemann et al., 1993). A recently determined crystal structure of flurbiprofen-bound CYP2C9 
indicates that the interaction of the carboxylate anion of flurbiprofen with a complex of hydrogen-
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bonded residues, Arg-108, Asp-293, and Asn-289, orients the substrate for regioselective 
hydroxylation (Wester et al., 2004). Moreover, the identification of this anionic-binding site helps 
explain how CYP2C9, an enzyme that has a relatively large active site, is able to catalyze the 
regioselective hydroxylation of small molecules such as the NSAIDS with high catalytic efficiency. 
 
• CYP2C19 
While CYP2C19 is not a major human CYP, it does illustrate two features of this enzyme family 
that are worth highlighting. First, it is 91% structurally homologous with CYP2C9 and yet the two 
enzymes have distinct substrate selectivity (Rettie et al., 2000). It is not particularly active in 
metabolizing the substrates that characterize CYP2C9 nor does it favour anionic substrates. Defining 
substrates include the anticonvulsant, mephenytoin, and the proton-pump inhibitor, omeprazole, 
neither of which is a substrate for CYP2C9. This suggests that relatively limited structural changes 
can have profound effects on substrate selectivity despite the fact that all the CYPs utilize the same 
activated oxygen species. Indeed, a change as limited as a single amino acid in an enzyme that is 
comprised of as many as 500 amino acids can have a major effect. For example, the I359L allelic 
variant of wild-type CYP2C9 is much less effective in metabolizing (S)-warfarin, the 
pharmacologically active enantiomer of racemic warfarin. In vitro, kinetic analysis of CYP2C9 
I359L indicated that the mutant metabolized (S)-warfarin with a fivefold lower Vmax and a fivefold 
higher Km than the wild-type CYP2C9 (Haining et al., 1996), suggesting that individuals who carried 
this mutant would be much more sensitive to the effects of the anticoagulant and require a much 
lower dose. This indeed has been found to be the case (Steward et al., 1997).  
The second important feature of CYP2C19 is that it is the first isoform to illustrate the potential 
importance of mutant forms of the enzyme to therapeutic outcome using standard dosing. The 4-
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hydroxylation of (S)-mephenytoin is the major metabolic pathway leading to the elimination and 
termination of the anticonvulsant activity of (S)-mephenytoin. CYP2C19 is the cytochrome CYP that 
catalyzes this metabolic transformation. However, in early studies the ability to metabolize 
mephenytoin seemed to vary within the population such that two distinct groups could be identified: 
extensive metabolizers and poor metabolizers. It turns out that a defective mutant form of CYP2C19 is 
carried by 4% of Caucasians but a full 20% of Asians. Thus, it is clear that if effective therapeutics is to 
be achieved, particularly with drugs with a narrow therapeutic index, knowledge of the metabolism of 
the drug and the enzymes and possible enzyme variants that control its metabolism is critical. 
 
• CYP2D6 
CYP2D6 can be considered a major contributor to the metabolism of a significant number of 
potent drugs used in human therapy, even though the amount of CYP2D6 present in human liver is 
generally less than 10% (Shimada et al., 1994) of the total amount of the cytochrome CYP present in 
human liver. From the perspective of substrate preference, CYP2D6 prefers basic substrates. Since 
most active central nervous system drugs are bases, it is hardly surprising that CYP2D6 plays an 
important role in the metabolic processing of these agents. A recent compilation listed 56 drugs 
where CYP2D6 is the primary or one of the major cytochrome CYP responsible for their metabolism 
(Zanger and Eichelbaum, 2000). Typical examples include the benzylic hydroxylation of the 
antidepressive agent, amitriptyline, the O-demethylation of the analgesic, codeine, the N-dealkylation 
of the antipsychotic, haloperidol, and the 4-hydroxylation of the antihypertensive, propranolol. In 
contrast, the antiarrhythmic agent, quinidine (also a base), is a potent (sub-µM) inhibitor of the 
enzyme. This fact illustrates that while the basic properties of quinidine insure that it has affinity for 
CYP2D6, affinity does not guarantee that the substrate will properly orient in the active site of the 
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enzyme with respect to the active oxidant, FeO3+, for efficient metabolic transformation. Thus 
quinidine could be considered as a “silent substrate” of CYP2D6, i.e., a compound that is a highly 
effective inhibitor by virtue of its affinity for the enzyme but one that is a poor substrate by its failure 
to achieve an efficient catalytically susceptible orientation. Silent substrates are potentially important 
causes of drug interactions because if they are present in vivo with another drug whose metabolism is 
governed by an enzyme that they potently inhibit, an exaggerated pharmacological response would 
result (Uetrecht and Trager, 2007). 
Like CYP2C19, CYP2D6 exhibits a common genetic polymorphism. In fact it was the first 
cytochrome P450 for which a genetic polymorphism was clearly established (Meyer and Zanger, 
1997). Historically, the two drugs that defined the polymorphism and indicated that individuals 
within the European population could be categorized as either extensive metabolizers or poor 
metabolizers were the antihypertensive agent, debrisoquine, and the labor-inducing agent, sparteine. 
About 5–10% of this population was found to be poor metabolizers and has little capacity to convert 
either of these two drugs to their major metabolites, 4-hydroxydebrisoquine and 5-dehydrosparteine. 
While the clinical usefulness of both the drugs has been superseded by the development of better 
agents, they can still be effectively used as analytical tools to evaluate the catalytic activity of 
CYP2D6 in vivo in an individual or in vitro in a liver sample (Uetrecht and Trager, 2007). 
 
• CYP2E1 
Chronic exposure of rats to ethanol leads to enhanced cytochrome P450 activity. After discovery 
of the phenomenon, the enhanced activity was soon characterized as being primarily due to the 
induction of a single CYP. This enzyme was subsequently identified as CYP2E1 (Raucy and 
Carpenter, 2000). Later studies with the selective CYP2E1 substrate, chlorzoxazone, confirmed that 
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chronic ethanol ingestion also led to the selective induction of CYP2E1 in humans. Ethanol is both an 
inducer and substrate of CYP2E1. Indeed, CYP2E1 seems to be structurally geared to favour small 
volatile molecules such as ketones, aldehydes, alcohols, halogenated alkenes, and alkanes as 
substrates (Koop, 1992). Moreover, many of these same compounds, like ethanol, are inducers of the 
enzyme. A major mechanism by which this diverse group of compounds appears to initiate induction 
is by inhibiting normal enzyme degradation.  
The apparent preference for small molecules suggests that CYP2E1 has a restricted active site. 
This simple observation is supported by the formation of aryl–iron complexes (Fe–Ar) in the 
reactions of human CYP2E1 with phenyldiazene, 2-naphthylhydrazine and p-biphenylhydrazine 
(Mackman et al., 1996).  
Since a number of CYP2E1 substrates are industrial chemicals to which large numbers of people 
are exposed, induction has significant toxicological implications. It turns out that the structural 
properties of many CYP2E1 substrates can lead to the formation of chemically reactive metabolites 
upon enzyme-catalyzed oxidation. There is evidence that a number of these reactive metabolites are 
either carcinogenic or generate the expression of other toxicities. For example, chloroform is 
converted to phosgene, other halohydrocarbons can similarly be metabolized to acid chlorides or 
reductively transformed to reactive radicals, e.g., CCl4 to •CCl3, ethanol is converted to acetaldehyde, 
and alkenes are converted to epoxides, e.g., butadiene to butadiene monoepoxide. In addition, 
CYP2E1 generates methyl carbonium ion, a reactive methylating species capable of methylating 
DNA, subsequent to the N-demethylation of tobacco-generated nitrosoamines, e.g., N, N-
dimethylnitrosoamine, to N-methylnitrosoamine, methyl carbonium ion, water, and nitrogen 
(Uetrecht and Trager, 2007). 
34 
 
1.7.3. CYP3 family 
 
 
The CYP3 family is often considered the most important of the drug-metabolizing enzymes in 
humans, particularly CYP3A4, which metabolizes the majority of exogenous compounds that 
potentially enter the human body, in addition to a few endogenous substrates such as steroids (Lewis, 
2001; Parkinson, 2001). 
 
• CYP3A4 
Out of all the cytochrome P450s involved in human drug metabolism, CYP3A4 could be 
considered to be the most important by virtue of the fact that at least 50% of marketed drugs that are 
metabolized by CYPs are metabolized by the CYP3A4 (Shimada et al., 1994). Generally, it is the 
most abundant CYP present in human liver, averaging 29% in a study that determined CYP content 
in 60 human liver samples. Like all CYPs, percent content of any specific CYP can vary between 
individuals. The variability of CYP3A4 between individuals can be as high as 20-fold (Wrighton and 
Thummel, 2000). 
In addition to being the most abundant CYP in human liver, it is also the most abundant CYP in 
human intestinal mucosa averaging about 40% of what is found in liver. The high intestinal content 
of CYP3A4 can have a major effect on the bioavailability of orally administered drugs, because any 
orally administered drug must first pass through the intestinal mucosa before reaching the systemic 
circulation. Thus, a significant fraction of a first-pass metabolism effect might be due to the passage 
through the intestine and exposure to CYP3A4 before the drug reaches the liver via the portal vein, 
where it is again exposed to metabolism in the liver before it enters the systemic circulation (Uetrecht 
and Trager, 2007). 
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A number of substrates of CYP3A4 have been used as in vivo and/or in vitro markers of the 
enzyme activity to determine CYP3A4 content in human subjects or in liver or intestinal 
preparations. Examples include the N-demethylation of erythromycin, the ring oxidation of 
nifedipine, the 6β-hydroxylation of testosterone, and the 1-hydroxylation of midazolam. Out of these 
examples, the 1-hydroxylation of midazolam has properties that make it the method of choice, 
particularly as an in vivo probe. Midazolam is completely adsorbed, has a half-life of 60 to 90 
minutes, the 1-hydroxylation process is specific to CYP3A4 at the concentrations used, and it appears 
not to be a substrate for p-glycoprotein, the efflux pump present in the intestinal mucosa. This means 
that, if desired, it would be possible to independently assess the CYP3A4 content in liver and 
intestine within a subject by simultaneously administering oral and intravenous doses (one dose being 
labelled with a stable or radioactive isotope to distinguish it from the other dose) of midazolam. 
The implication of the effectiveness of CYP3A4 in catalyzing the biotransformation of so many 
drugs in current use implies that at least potentially clinically significant drug interactions might be 
associated with the use of these drugs. Clearly, one might expect to observe a drug interaction when a 
drug primarily metabolized by CYP3A4 is co-administered with another medication that is also either 
a substrate or inhibitor of this enzyme. In clinical practice, however, this turns out not to be the major 
problem that might have been expected. In order for a significant interaction to occur, the enzyme 
must be substantially inhibited and this generally requires a concentration of the inhibitor at the 
active site of the enzyme well in excess of its Ki. For many inhibitors, the in vivo concentration 
achieved at the active site of the enzyme is less than its binding constant, i.e., Ki. Thus, significant 
interactions generally arise from very potent competitive inhibitors, i.e., ones with a Ki in the low 
micromolar or sub-micromolar region, or time-dependent inhibitors, i.e., ones that covalently modify 
the enzyme (Uetrecht and Trager, 2007). Also, variations in levels of CYP3A4 can cause clinical 
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problems when the therapeutic window is narrow. For instance, low cyclosporine levels will not 
prevent organ rejection during transplant but high levels can cause renal toxicity, so adjustment of the 
dose must be done very carefully (Yee et al., 1984).  
The effect of disease on CYP3A4 has been considered. CYP3A4 expression appears to be 
decreased as a result of liver cirrhosis or cancer (El Mouelhi, 1984). CYP3A4 levels were also 
decreased in celiac disease and reversed by a change in diet (Lang et al., 1996).   
The influence of herbal medicines on CYP3A4 represents an important issue in herb-drug 
interacions (Zhou et al., 2003). One of the most studied issues is St. John’s wort, which induces 
CYP3A4 by virtue of being an agonist of PXR receptor (Moore et al., 2000). The induction of 
CYP3A4 by St. John’s wort has been responsible for the loss of the effectiveness of oral 
contraceptives (Henderson et al., 2002).  
Another issue is the inhibition of CYP3A4 by grapefruit juice and other fruit juices, first reported 
by Bailey (Bailey et al, 1990). The effect was rather specific for grapefruit and a few other citrus 
fruits (not orange), and warning labels now include this contraindication for many drugs (Greenblatt 
et al., 2001). 
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1.7.4. CYP4 family 
 
The CYP4 family of isozymes is important in metabolizing endogenous fatty acids. Thus, this 
family typically binds substrates with a carboxylic acid moiety at the terminus of aliphatic chains and 
facilitates the ω-hydroxylation (and ω – 1 hydroxylation) of long chain fatty acids (Lewis, 2001). 
These enzymes do not play a major role in xenobiotic metabolism (Parkinson, 2001).  
 
 
1.8. NADPH-cytochrome P450 reductase 
 
 
It is well known that NADPH P450 reductase is a necessary component in the monooxygenase 
cycle and that high levels of the reductase promotes the catalytic activity of CYP-enzymes by 
supplying electrons to the CYP-cycle (Nakajima et al., 2002; Schenkman and Jansson, 2003; Wu et 
al., 2005). 
Cytochrome P450-mediated microsomal electron transport is responsible for oxidative 
metabolism of both endogenous compounds, including fatty acids, steroids, and prostaglandins, and 
exogenous compounds ranging from therapeutic drugs and environmental toxicants to carcinogens. It 
is mediated by a multicomponent monooxygenase system, in which reducing equivalents from 
NADPH ultimately are transferred to molecular oxygen  
(Shen & Kasper, 1993).  
In its simplest form, the monooxygenase sytem consists of NADPH-cytochrome P450 reductase 
(CPR; NADPH-ferrihemoprotein reductase) and one of many cytochrome P450 isenzymes (Williams 
& Kamin, 1962; Phillips & Langdon, 1962). Both CPR and microsomal cytochromes P450 are 
integral membrane proteins, and CPR is one of only two known mammalian enzymes containing both 
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FMN and FAD as prosthetic groups. Other physiological electron acceptors of CPR include 
microsomal heme oxygenase (Schacter et al., 1972), and cytochrome b5 (Enoch & Strittmatter, 1979) 
and, although non-physiological, CPR is capable of transferring reducing equivalents to cytochrome 
c (Horecker, 1950).  
CPR accepts a pair of electrons from NADPH as a hydride ion, with FAD and FMN being the 
port of entry and exit, respectively, and transfers these electrons one at a time to cytochromes P450. 
Cytochromes P450, in turn, use these reducing equivalents for the hydroxylation of a variety of 
substrates. The redox potentials of each flavin half-reaction in the native enzyme have been 
determined by potentiometric titrations (Iyanagi et al., 1974; Vermilion & Coon, 1978). The enzyme 
cycles between 1e- and 3e- reduced levels (or 2e- and 4e-), with the one-electron-reduced semiquinone 
of the FMN being the highest oxidation state during catalytic turnover (Masters et al., 1965; Backes 
& Reker-Backes, 1988).  
The enzyme has two functional domains, a hydrophobic N-terminal membrane-binding domain 
and a hydrophilic C-terminal catalytic domain that is comprised of several structural domains. The 
hydrophobic N-terminal domain (6 kD) serves to anchor the protein molecule to the endoplasmic 
reticulum and nuclear envelope (Figure 3) (Kasper, 1971), thus ensuring proper spatial interaction for 
electron transfer between the reductase and cytochromes P450. 
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Figure 3. Electron transfer to cytochrome P450. 
Source : http://www.uky.edu/Pharmacy/ps/porter/CPR_enzymology.htm 
 
 
Chemical cross-linking and modification studies have shown that CPR contains multiple 
carboxylate groups, presumably contributed by the acidic amino acids aspartate and glutamate 
(Nisimoto, 1986). These charge groups pair with basic amino acids (lysines, arginines) on the various 
electron acceptor proteins.  In addition, cytochrome P450 forms a dipole across the molecule, with 
the positive charge at the proximal face of the protein where the heme makes its closest approach to 
the surface (Hasemann et al., 1995). This is thought to be the surface most suitable for electron 
transfer from CPR.  While electrostatic forces may serve to connect and orient the pair, hydrophobic 
forces contributed by nonpolar amino acids (leucine, tryptophan, valine, and others) may be 
responsible for bringing the two proteins close enough together for electron transfer (Inano and 
Tamaoki, 1985). 
Site-directed mutagenesis studies have identified two clusters of acidic amino acids in the FMN 
domain of CPR (consistent with its role as the electron donor flavin) that, upon mutation to nonacidic 
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amino acids, disrupt the interaction with cytochrome P450 and cytochrome c (Shen and Kasper, 
1995). The 3-dimensional structure of the reductase FMN domain-P450 BM3 complex (shown below 
in figure 4) supports the above model for interaction of these proteins (Servrioukova et al., 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Three-dimensional structure of FMN domain of CPR 
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PART II: INFLAMMATION AND CYTOCHROME P450 
 
 
Inflammation (Latin, inflammatio, to set on fire) is the complex biological response of vascular 
tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It is a protective attempt 
by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue.  
Inflammatory responses are complex, and occur in response to a number of pathological 
disorders, including infection, tissue damage, burns, trauma, tumors, and autoimmune disease. The 
entire process usually is initiated by the activation of inflammatory cells, such as macrophages or 
neutrophils, and is characterized by the release of cytokines, mediators, acute phase proteins, and 
hormones. The release of these agents results in the acute phase response, which includes the 
formation of a number of proteins. Because inflammation is a key component of many disease states, 
the alteration of drug biotransformation during any inflammatory process has to be taken into account 
in clinical therapeutics (Renton, 2001). 
Samaras and Deitz have first documented that CYP was altered during activation of host defence 
mechanisms, in an abstract published in 1953 (Samaras and Deitz, 1953). They noted that the actions 
of pentobarbital were greatly exaggerated in rats that had been treated with a Tryptan blue particulate 
that had activated the immune system.  
The concept that infections and inflammatory compounds could alter drug disposition originated 
23 years later in the late Gil Mannering’s laboratory at the University of Minnesota (Renton and 
Mannering, 1976). Agents such as tryptan blue dye, symosan, dextran sulphate, and latex beads have 
been assumed to lower CYP by activating an inflammatory response within the liver macrophages 
(Morgan, 1997). Inflammation in sites outside the liver, such as the administration of irritants, 
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adjuvants, or vaccines, has similar effects. In a classic model of inflammation, the subcutaneous 
administration of turpentine causes a significant decrease in a number of CYP-dependent reactions 
(Chindavijak et al., 1987; Morgan, 1989; Barakat & du Souich, 1996; El-Kadi et al., 1997; El-Kadi & 
du Souich, 1998; Bleau et al., 2000).  
The first report of altered drug disposition in humans with an infection showed that the clearance 
of theophylline was diminished during upper respiratory tract infections caused by influenza or 
adenovirus (Chang et al., 1978). Several reports followed indicating that the use of theophylline in 
children with infections resulted in the accumulation of the drug in plasma to dangerous levels 
(Fleetham et al., 1978; Clarke & Boyd, 1978; Walker & Middlekamp, 1982; Greenwald & Koren, 
1990). The accumulation of theophylline to levels in brain causing convulsions in several asthmatic 
children occurred during influenza A epidemic in Seattle (Woo et al., 1980; Kraemer et al., 1982). 
This effect of influenza on theophylline disposition has been reported by others. For instance Koren 
and Greenwald reported that routinely monitored theophylline levels tended towards the toxic range 
during influenza epidemics (Koren and Greenwald, 1985).  
Changes in drug clearance have also been observed in disease states that involve an 
inflammatory response. Inflammation following surgical procedures reduced CYP3A4 activity as 
measured by the erythromycin breath test (Haas et al., 2003). The enzyme activity gradually 
diminished over a period of three days to produce a significant decrease at that time. The reduction in 
CYP3A4 activity at all times after surgery correlated with the concentrations of IL-6 present in 
blood. This study suggests that the presence of acute inflammation after elective surgery may impact 
on the metabolism and clearance of a large group of commonly used drugs.  
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2.1. Mechanisms of cytochrome P450 down-regulation  
 
 
The down-regulation of CYP concentrations during infection and inflammation is almost 
certainly a complex and multifaceted process that involves a number of possible factors and the 
formation of a chain of mediators, leading to an eventual effect at the level of enzyme expression or 
function. Many of the conditions and immune modulators that alter CYP expression elicit a large 
number of effects that are mediated by a variety of mediators and intermediates. Although some have 
suggested that a common mediator may be involved, the diversity of agents down-regulating a 
variety of CYP isoforms would make this unlikely. There is much evidence to support the idea that 
the enzyme form and the “immune” activator determine the spectrum of response and its time course 
(Morgan, 1997).  
 
2.1.1. Pro-inflammatory cytokines (Il-1, Il-6, IFN, TNF) 
 
 
Since first suggested in 1976 that interferons could trigger a down-regulation of cytochrome 
P450 enzymes (Renton & Mannering; Leeson & Biedenback), it has been a common finding that the 
production and release of cytokines play a key role in the intermediate pathways and signal 
transduction that leads to the loss in cytochrome P450 (Morgan, 2001; Renton, 2001; Morgan, 1997; 
Renton and Knickle, 1990). Recombinant interferons of the three major classes have been shown to 
depress most isoforms of the cytochrome P450 in rodents (Parkinson, et al., 1982; Singh, Renton and 
Stebbing 1982; Calleja et al. 1998; Carelli et al. 1996).  
Other cytokines including IL-1α, IL-1β, IL-2β, IL-6, TNF-α, and TGF-β have also been shown 
to mimic infection and inflammation by depressing several cytochrome P450 isoforms in rodents and 
in hepatocyte cultures (Fukuda et al. 1992; Clark et al., 1995; Sanne & Krueger, 1995; Barker et al, 
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1992; Wright & Morgan, 1991; Nadin et al, 1995). A recent review and tabular data collection 
indicates that many of the cytochrome P450 isoforms that are involved in steroid synthesis pathways 
in different mammalian species are modulated by cytokines (Herrmann et al., 2002). IL-6 appears to 
have a widely differentiated response on cytochrome P450 isoforms and has a dose dependent 
sensitivity often absent with other cytokines (Chen et al, 1992; Chen et al, 1994). 
  
2.1.2. Nitric Oxide 
 
 
Another mediator that has received much attention is nitric oxide (NO) that is produced by 
NOS2 in response to inflammation. There is no doubt that considerable amounts of NO is produced 
in mammalian species in response to inflammatory stimuli that could reduce cytochrome P450 
activity by decreasing mRNA and protein levels, by altering the protein or by binding to the heme 
moiety (Liaudet et al., 2000). Although a number of studies have demonstrated that inflammation-
mediated reduction of cytochrome P450 correlate with NO production, and that this decrease can be 
blocked by NOS inhibitors, other studies have shown that inhibition of NOS has no effect in 
modulating the effect of inflammation on cytochrome P450 isoforms (Hodgson & Renton, 1995; 
Monshouwer et al, 1996; Sewer & Morgan, 1997).  
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2.1.3. Oxidative Stress 
 
 
Several other mechanisms underlying the down-regulation and/or the decrease in activity of 
cytochrome P450 enzymes have been suggested, including oxidative stress and the production of 
reactive oxygen mediators (Renton, 2001; Morgan, 1997). However, these mechanisms may play a 
role only for some specific cases and at specific levels of signal transductions pathways and appears 
to have a minor role in the widely reported down-regulation. 
 
2.1.4. Decrease in Gene Expression 
 
 
At the level of cytochrome P450 isoform expression itself, it is fairly well accepted that for most 
of the enzyme forms there is a decrease in the specific mRNA and subsequent protein synthesis 
during inflammation, infection or following the administration of cytokines (Renton, 2001; Morgan, 
2001). For most cytochrome P450s the reduction in mRNA precedes the decrease in enzyme and its 
activity, and the entire process is following other pattern as that of enzyme induction processes 
(Renton, 2004). The down-regulation of cytochrome P450 isoforms involves an intracellular protein 
intermediate, assumed to be a transcription factor (Moochhala & Renton, 1991).  
 
2.1.5. Intra-cellular Signalling Pathways 
 
 
The response to cytokines is closely associated to the activation of transcription factors such as 
NF-κB or C/EBP (CCAAT-enhancer binding protein) (Morel & Barouki, 1998; Iber et al, 2000).  In 
addition, the nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor 
(PXR) play a role in the inflammation mediated decrease in CYP2B and CYP3A (Van Ess et al, 
2002; Sachdeva et al, 2003; Beigneux et al, 2002). From all evidence to date, it is clear that the 
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decrease of most cytochrome P450 isoforms during inflammatory responses involves a decrease in 
transcription following changes of the expression and regulation of a variety of transcription factors. 
Changes in specific transcription factors are targeted to specific cytochrome P450 isoforms. The 
apparent lack of evidence for the involvement of a single common transcription factor for all 
cytochrome P450 forms is likely a good explanation to account for the differential responses of the 
various enzyme families to diverse inflammatory stimuli (Renton, 2004). 
 
2.1.6. Post Transcriptional Mechanisms 
 
 
A few studies have suggested that for some cytochrome P450 isoforms inflammation mediated 
depression is partly due to post transcriptional mechanisms (Morgan, 1989; Delaporte and Renton, 
1997). While it is clear that the decrease in cytochrome P450 isoforms can occur at post 
transcriptional stages, this mechanism only accounts for a small proportion of the reduction that 
occur during inflammatory responses and it appears to involve more frequently the CYP3A family. 
The vast majority of reports indicate that the down-regulation of most enzymes occurs at the level of 
transcription (Renton, 2004).  
 
At the practical level more evidence continues to emerge indicating that drug clearance can be 
significantly changed in humans during disease states that involve an inflammatory component. With 
the recognition that most isoforms of cytochrome P450 are modified during periods of inflammation 
or infection, there may be a need to alter drug therapy during these periods and to be particularly 
vigilant at monitoring for untoward drug responses (Renton, 2004). 
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PART III: OSTEOARTHRITIS 
 
The definition of osteoarthritis (OA) has evolved over the past two decades and now recognizes 
OA as a syndrome with a complex aetiology rather than as a single disease entity. Osteoarthritis can 
be defined as a gradual loss of articular cartilage, combined with thickening of the subchondral bone, 
bony outgrowths (osteophytes) at joint margins, and mild, chronic nonspecific synovial 
inflammation. The difference between physiologic aging of the cartilage and OA cartilage is not 
sharp. However, three cartilage stages can be identified: stage I, normal cartilage; stage II, aging 
cartilage; and stage III, OA. 
 
3.1. Normal Cartilage 
 
 
Normal cartilage has two main components. One is the extracellular matrix, which is rich in 
collagens (mainly types II, IX, and XI) and proteoglycans (mainly aggrecan). Aggrecan is a central 
core protein bearing numerous glycosaminoglycan chains of chondroitin sulfate and keratan sulfate, 
all capable of retaining molecules of water. The second component consists of isolated chondrocytes, 
which lie in the matrix. The matrix represents 95% of the cartilage and the chondrocytes only 5%. 
The matrix components are responsible for the tensile strength and resistance to mechanical loading 
of the articular cartilage (Klippel, 2008).  
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3.2. Osteoarthritic Joints 
 
 
Osteoarthritic joints have abnormal cartilage and bone, with synovial and capsular lesions 
(Kenneth et al., 2003). Macroscopically, the most characteristic elements are reduced joint space, 
formation of osteophytes (protrusions of bone and cartilage) mostly at the margins of joints, and 
sclerosis of the subchondral bone (Figure 5). 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Standing anteroposterior (A) and standing flexed postero-anterior (B) views of the right knee.a  
 
aIn (A), no significant narrowing of the joint is identified although osteophytes and subchondral sclerosis, 
indicative of osteoarthritis, are evident. In (B), however, the standing flexed view demonstrates complete 
articular cartilage loss in the lateral compartment. 
 
 
B
 
A 
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3.3. Enzymes Involved in Cartilage Degradation 
 
 
The main proteinases involved in the destruction of the cartilage in OA are the matrix 
metalloproteinases (MMPs) (Cawston, 1998). There are at least 18 members of this gene family of 
neutral Zn2+ metalloproteinases. Because they are active at neutral pH, the MMPs can act on the 
cartilaginous matrix at some distance from the chondrocytes. They can be synthesized by 
chondrocytes and synoviocytes under the influence of cytokines. 
The activities of MMPs are strictly controlled by stoichiometric inhibition with specific 
inhibitors, the tissue inhibitors of metalloproteinases (TIMP1-4). Therefore, the balance between the 
amounts of MMPs and TIMPs in cartilage determines if cartilage is degraded (Dean et al., 1989). 
MMPs produced by the chondrocytes and released into the extracellular matrix are activated by an 
enzyme cascade involving serine proteinases (plasminogen activator, plasminogen, plasmin), free 
radicals, cathepsins, and some membrane-type MMPs. This enzymatic cascade is regulated by natural 
inhibitors, including the TIMPs and the inhibitors of the plasminogen activator. MMP-13 is elevated 
in OA joint tissues, particularly in articular cartilage, and colocalizes with type II collagen cleavage 
epitopes in regions of matrix depletion in OA cartilage (Dean et al., 1989).  
The other enzymes that can degrade type II collagen and proteoglycans are the cathepsins. 
They are active only at low pH and include the aspartate proteinases (cathepsin D) and cysteine 
proteinases (cathepsins B, H, K, L, and S) that are stored in chondrocyte lysosomes and released into 
the pericellular microenvironment. Glycosidases also may be important, because proteoglycans are 
very rich in carbohydrate chains. Although hyaluronidases are not present in cartilage, other 
glycosidases may contribute to the degradation of proteoglycans (Cawston et al., 1998).  
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3.4. Cytokines 
 
Although OA has often classified as a non-inflammatory disease, numerous studies have shown 
that inflammatory cytokines provide essential biomechanical signals that stimulate chondrocytes to 
release cartilage-degrading enzymes. Pro-inflammatory cytokines synthesized by chondrocytes and 
synoviocytes bind to specific receptors on chondrocytes. These bound cytokines trigger the 
transcription of the MMP genes, and the genes’ products are exported from the cell in an inactive 
form.  It is generally accepted that IL-1 is the pivotal cytokine released during inflammation of the 
osteoarthritic joint (Jacques et al., 2006).  Other cytokines are released, including chemokines (IL-8), 
growth-regulated oncogene (GRO) alpha, macrophage inflammatory proteins (MIP-1 alpha and MIP-
1 beta). Some of these cytokines and chemokines may be regulatory [e.g., IL-6, IL-8, lymphocyte 
inhibitory factor (LIF)], or inhibitory (e.g., IL-4, IL-10, IL-13, IFN-γ). IL-1 receptor antagonist, IL-4, 
IL10, and IL-13 prevent the secretion of some MMPs, and may increase the synthesis of TIMPs. In a 
more general way, IL-4 and IL-13 counteract the catabolic effects of IL-1. Finally, IL-1 alters the 
quality of the cartilage matrix by decreasing the synthesis of type II and IX collagens, while 
increasing the synthesis of type I and type III collagens.  
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3.5. Lipid Mediators 
 
 
The eicosanoids also can take part in chondrocyte activation (Goldring and Berenbaum, 2004). 
Prostaglandins, produced after activation of phospholipases A2, cyclooxygenases (mainly the 
cyclooxygenase-2 isoform) and prostaglandin synthases (mainly the microsomal prostaglandin E 
synthase-1) by proinflammatory cytokines, can favour  the synthesis of MMPs by activating the cell 
via specific cellular or/and nuclear prostaglandin receptors (Goldring and Berenbaum, 2004). Among 
the eicosanoids, prostaglandin E2 seems to be the main lipid mediator produced by synovial cells, 
chondrocytes, and subchondral osteoblasts and involved in cartilage degradation in OA. 
 
3.6. Reactive Oxygen Species 
 
 
Reactive oxygen species (ROS) play a crucial role in the regulation of a number of basic 
chondrocyte activities, such as cell activation, proliferation, and matrix remodelling. However, 
when ROS production exceeds the antioxidant capacities of the cell, an oxidative stress occurs, 
leading to structural and functional cartilage damages like cell death and matrix degradation 
(Henrotin et al., 2005). 
Nitric oxide (NO) is a gas synthesized by way of the oxidation of L-arginine by the NO 
synthases (NOS). Chondrocytes produce large amounts of NO after up-regulation of the inducible 
NOS gene (iNOS or NOS2) by cytokines. Most in vitro studies indicate that NO is partly responsible 
for the blockade of glycosaminoglycan and collagen synthesis by IL-1, and may contribute to the 
activation of the latent forms of MMPs. NO may also mediate the IL-1–stimulated synthesis of MMP 
mRNA and protein, and may contribute to chondrocyte cell death by interfering with survival signals 
from the extracellular matrix. However, NO may have anabolic and anticatabolic effects in cartilage 
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under certain conditions. Therefore, the actual role of NO in the degradative process of OA is not 
clear (Abramson et al., 2001).              
                                          
3.7. Matrix Degradation Products 
 
 
The products of matrix degradation, such as fibronectin fragments, can activate chondrocytes 
through integrin-type receptors that will increase the synthesis of MMPs. These products can 
stimulate or activate other factors, such as catabolic cytokines, that amplify the damage. The damage, 
in turn, enhances the concentrations of the degradation products themselves, as in a positive feedback 
loop (Peters et al., 2005). 
 
3.8. Mechanical Stress 
 
 
Along with chemical mediators, biophysical mediators could also be directly involved in 
chondrocyte activation in OA. Compressive, but also shear and stretch, stresses occur on cartilage. 
Interestingly, there is considerable evidence that interactions between biomechanical factors and pro-
inflammatory mediators are involved in the initiation and the progression of OA (Guilak et al., 2004). 
In vivo studies have shown increased concentrations of inflammatory cytokines and mediators in the 
joint in mechanically induced models of osteoarthritis. In vitro explant studies confirm that 
mechanical load is a potent regulator of matrix metabolism, cell viability, and the production of pro-
inflammatory mediators such as NO and prostaglandin E2. Chondrocytes have receptors for 
responding to mechanical stress and can respond to direct biomechanical perturbation by up-
regulating synthetic activity or inflammatory cytokines, which are also produced by other joint 
tissues. Chondrocytes express several members of the integrin family, and these can serve as 
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receptors for fibronectin (alpha 5 beta 1), types II and VI of collagen (alpha 1 beta 1, alpha 5 beta 1, 
alpha 10 beta 1), laminin (alpha 6 beta 1), and vitronectin and osteopontin (alpha V beta 3). Some of 
these receptors are sensitive to prolonged changes in pressure (mechanoreceptors). Injurious static or 
dynamic compression stimulates depletion of proteoglycans and damage the collagen network and 
decreases the synthesis of cartilage matrix proteins, whereas low intensity dynamic compression 
increases matrix synthetic activity. Certain types of mechanical stress and cartilage matrix 
degradation products are capable of stimulating the same signalling pathways as those induced by IL-
1 and tumor necrosis factor alpha (TNF-α). These signalling pathways involve cascades of kinases, 
including the stress-activated protein kinases (SAPKs), including the c-Jun N-terminal kinases 
(JNKs) and p38 MAP kinase, phosphatidylinositol- 3′-kinase (PI-3K), and IκB kinases,  leading to 
the nuclear translocation of NF-κB. Because these signalling pathways may also induce the 
expression of the genes encoding these cytokines, it remains controversial whether inflammatory 
cytokines are primary or secondary regulators of the progressive cartilage destruction in OA (Yasuda 
et al, 2002; Loeser et al, 2005). 
 
3.9. Chondroitin sulfate 
 
 
Chondroitin sulfate (CS) is a linear heteropolysaccharide chain of repeating disaccharide units of 
d-glucuronic acid and d-galactosamine sulfated at the C-4 and/or C-6 positions, covalently linked to 
proteins forming proteoglycans; the proteoglycan aggrecan contains hyaluronic acid instead of CS 
(Guilak et al., 2004). Joint cartilage consists of chondrocytes (5% of the volume) embedded in a 
matrix of fibrous collagen within a concentrated water proteoglycan gel. Damage of the structure 
collagen/proteoglycans and synovitis are the basis of osteoarthritis (Bhosale and Richardson, 2008).  
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While it is a prescription or over-the-counter drug in 22 countries, chondroitin is regulated in the 
U.S. as a dietary supplement by the Food and Drug administration. As a result, in chondroitin sulfate 
supplements, there are no mandatory standards for formulation, and no guarantee that the product is 
correctly labelled. This is not the case of Europe where there is a chondroitin sulfate formulation 
approved as a drug and considered as the reference product, with evidenced efficacy and safety 
demonstrated by clinical trials in osteoarthritic patients (Vergés and Castañeda-Hernández, 2004). 
 
3.10. Chondroitin sulfate in osteoarthritis 
 
 
Randomized clinical trials in patients with OA have shown that CS reduces pain and improves 
articular function (Uebelhart et al., 2004), reduces joint swelling and effusion, and prevents joint 
space narrowing of the knee (Uebelhart et al., 1998) and fingers (Rovetta et al., 2002) more 
effectively than placebo. According to these effects, CS has been classified as a symptomatic slow 
acting drug in osteoarthritis (SYSADOA). Because CS appears to slow down cartilage damage, CS 
has also been classified as a structure/disease modifying anti-osteoarthritis drug (S/DMOAD) 
(Uebelhart et al., 2004).  
 
3.11. Effect of CS on articular cartilage 
 
 
The complex clinical response to CS may tentatively be explained by the numerous effects that 
have been attributed to this drug. On the one hand, the decrease in pain and swelling may be 
explained by an anti-inflammatory effect of CS, probably through diverse mechanisms such as 
diminishing the expression of phospholipase A2 (PLA2) (Ronca et al., 1998), of cyclooxygenase-2 
(COX-2), and the concentrations of prostaglandin E2 (PGE2) (Chan, 2005; Orth, 2002; Bassleer, 
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2002). Moreover, CS reduces in joints the concentrations of pro-inflammatory cytokines, such as 
TNF-α (Campo 2003) and IL-1β (Chou, 2005), as well as systemic and joint concentrations of NO 
(Orth, 2002; Chan, 2005) and of reactive oxygen species (ROS) (Campo, 2003).  
There is evidence that in chondrocytes, CS diminishes IL-1β-mediated increase in MMP-2, 
MMP-3, MMP-9, MMP-13, and MMP-14 (Orth, 2002; Chan, 2005). On the other hand, it has been 
documented that hyaluronan and mixtures of low concentrations of CS and glucosamine were able to 
prevent the release of MMP-3 and MMP-13 triggered by fibronectin fragments (FN-f) (Homandberg 
et al., 2004; 2006). In subchondral bone, CS increases osteoprotegerin (OPG) and reduces the 
expression of receptor activator of nuclear factor-kappa B ligand (RANKL), effects that may result in 
the reduction of the resorptive activity (Tat et al., 2007). 
In chondrocytes, CS diminishes ERK1/2 phosphorylation and abrogates the phosphorylation 
of p38MAPK induced by IL-1β; as a consequence, CS reduces IL-1β-induced NF-κB nuclear 
translocation. However, CS does not reduce IL-1β-induced AP-1 nuclear translocation. On the 
other hand, CS decreases nitroprusside-induced apoptosis of the chondrocytes which is 
associated to p38MAPK activation (Jomphe et al., 2008). In chondrocytes, chondroitin 
disaccharides sulphated at positions 4 and/or 6, (1-4)-O-(D-glucopyranosyluronic acid)–(1-3)-O-
(2-N-acetamido-2-deoxy-D-galactopyranosyl-4/6-sulfate) (∆di-4S, ∆di-6S and ∆di-4,6S) reduce 
IL-1β-induced NF-κB nuclear translocation to a similar extent as CS, e.g. ∆di-4S, ∆di-6S and 
∆di-4,6S reduce NF-κB translocation (Figure 6). 
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Figure 6.  Effect of CS disaccharides sulphated in position 4 and/or 6 (∆di-4S, ∆di-6S, ∆di-4,6S) on Il-1β-
induced NF-κB nuclear translocation 
 
 
 
It has been widely documented that IL-1β-induced increase in expression of MMP-3 (Liacini et 
al., 2002; Schulze-Tanzil, 2004; Sylvester et al., 2001), MMP-9 (Lianxu, 2006), MMP-13 (Liacini et 
al., 2002; Mengshol, 2000; Wada et al., 2006), COX-2 (Wada et al., 2006; Berenbaum et al. 2003), 
NOS2, IL-1β and TNF-α (Wen et al., 2006; Hanada et al. 2002) is mediated by the activation and 
nuclear translocation of NF-κB and AP-1. Moreover, there is evidence that the activation of 
phospholipase A2 requires the activation of p38MAPK and ERK1/2 (Berenbaum et al., 2003), and 
that the induction of RANKL expression requires the activation of ERK1/2 and PI-3K/Akt pathways 
(Tsubaki et al., 2007). Since the above mentioned effects of IL-1β and of NF-f are mediated by the 
activation of p38MAPK and of ERK1/2, and the nuclear translocation of NF-κB, it has been 
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proposed that the pleiotropic effects of CS are dependent, at least in part, by its ability to inhibit 
p38MAPK and ERK1/2 phosphorylation and NF-κB nuclear translocation (Iovu et al., 2008). 
 
3.12. Effect of CS on the synovial membrane 
 
 
Synovial tissue from patients with early osteoarthritis show activated fibroblast-like 
synoviocytes (FLS), macrophages, T lymphocytes, and mast cells infiltration (Benito et al., 2005). 
FLS release IL-1β, IL-6, IL-8, MMP-1, MMP-2, MMP-3, MMP-13, MMP-14, MMP-16, TIMP-1, 
RANKL, transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and 
fibroblast growth factor (FGF).  
The role of NF-κB in the development of synovitis appears essential. In FLS, the production of 
IL-1β, IL-6, IL-8, MMP-1, and MMP-3, requires the activation and nuclear translocation of NF-κB 
(Xu, 2007; Lauder, 2007). Moreover, the activation of NF-κB increases FLS proliferation and 
transforms the phenotype of these cells to highly invasive cells with great motility and ability to 
secrete cytokines and MMP-13 (Li et al., 2006). Inhibition of the IκB kinase (IKK) complex impedes 
the phosphorylation of inhibitor of κB (IκBα) and as a consequence, prevents NF-κB activation. In 
synovial macrophages, inhibition of IKK diminishes IL-1β-induced production of IL-6; moreover, in 
rats with adjuvant-induced arthritis, intraarticular injection of a specific IKK-β inhibitor reduces 
arthritis activity and bone destruction; synovial inflammation is also decreased as documented by the 
reduction in synovial cellularity, TNF-α, IL-1-β concentrations, and reduction of the volume of the 
paw (Tas et al., 2006). These results were confirmed by administering in the articulation a dominant-
negative form of IKK-β that reduced synovial cellularity by 50%, and diminished synovial 
concentrations of IL-1β, TNF-α and MMP-3 (Tas et al. 2006). These results provide evidence that 
activation and nuclear translocation of NF-κB is an important step in the development of synovitis. 
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There is little information about the effect of osteoarthritis treatment on synovitis manifestations, 
e.g. joint swelling and effusion. The multicenter, double-blind, placebo- and celecoxib-controlled 
Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) assessed the effect of CS and 
glucosamine alone or in combination on joint swelling and/or effusion in 1583 patients with mild to 
severe knee osteoarthritis (Clegg et al. 2006). The patients received 1200 mg of CS, or 1500 mg of 
glucosamine or both CS and glucosamine, or 200 mg of celecoxib or placebo, daily for 24 weeks. 
The study demonstrates that CS diminished the percentage of patients with signs of synovitis (joint 
swelling and effusion) from 28.3% at baseline to 12.4% at the end of 24 weeks of treatment. It is of 
interest that the beneficial effect of CS was observed in the patients with mild pain (WOMAC pain 
scores 125 - 300). In patients with moderate to severe pain (WOMAC pain scores 301 – 400) 
receiving CS, the percent of patients with swelling and/or effusion tended to decrease from 30.0% at 
baseline to 14.9% (p = 0.3) at the end of follow-up.  
Further supporting that CS reduces the signs and symptoms of synovitis, a study showed that 
intra-articular injection of hyaluronate, a glycosaminoglycan with a mw of 8.4x105, to patients with 
rheumatoid arthritis improves local clinical symptoms, decreases synovial fluid, reduces 
prostaglandin E2 concentrations and diminishes pain (Goto et al. 2001).   
Several animal studies demonstrate that CS reduces the signs and symptoms of synovitis. In 
DBA/1J mice with a type II collagen-induced arthritis, treated for 9 weeks with various dosages of 
CS, the infiltration of inflammatory cells, granulated tissue formation, proliferation of synovial lining 
cells, paw edema and destruction of articular cartilage were partially prevented by treatment with 
1000 mg/kg/day of CS for 63 days (Omata et al. 2000). In dogs with unilateral carpal synovitis 
induced by injecting into the right radiocarpal joint chymopapain, prior treatment with CS reduces 
the extent of synovitis (Canapp et al., 1999). In rabbits with experimental OA, intra-articular 
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administration of N-acetylglucosamine elicited an anti-inflammatory effect and suppressed the 
synovitis (Shikhman et al. 2005).  
All these studies strongly support that in animal models and in humans, glycosaminoglycans 
reduce the synovitis. The mechanism of action underlying the reduction of synovitis signs by CS and 
other glycosaminoglycans remains incompletely characterized. It has been reported that chondroitin 
sulfate disaccharide ∆di-6S reduces IL-1β-induced nuclear translocation of NF-κB by 67% in 
synoviocytes (Alvarez-Soria et al., 2005). This observation is in agreement with the effect of CS and 
its ∆di-4S and ∆di-6S disaccharides in chondrocytes, e.g. they reduce NF-κB nuclear translocation 
(Iovu et al., 2008). Since oral CS increases plasma concentrations of ∆di-4S and ∆di-6S (Volpi, 
2002), it is conceivable that in humans, the decrease in synovitis signs produced by CS may be 
explained, at least in part, by the reduction in NF-κB nuclear translocation in synoviocytes and 
macrophages, with the subsequent diminution of activation of these cells and decrease in synovitis. 
In summary, CS and/or the sulfated disaccharides appear to elicit an anti-inflammatory effect at 
the synovial membrane and chondrocytes levels. Possibly, CS and/or disaccharides reduce the 
inflammatory reaction by diminishing NF-κB nuclear translocation (Figure 7). In the chondrocytes, 
this effect is mediated by the inhibition of p38MAPK phosphorylation and to a minor degree ERK1/2 
phosphorylation. Indeed, further studies are required to better characterize the precise mechanism of 
action underlying CS-induced improvement of synovitis.  
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Figure 7. Diagram depicting the potential sites of effect of CS and/or its disaccharidesa 
Source: Iovu et al., 2008 
 
aLocal microtraumas produce EMFs and FN-f that activate chondrocytes by increasing the nuclear 
translocation of NF-κB in the chondrocytes, synovial macrophages and synoviocytes. NF-κB has a key role in 
the pro-inflammatory activation of chondrocytes, and synovial macrophages, mast cells, T-cells and 
synoviocytes and in the release of cytokines and MMPs that will sustain cartilage and subchondral bone 
destruction. 
 
 
 
 
Conclusion 
 
 
Patients with osteoarthritis are usually multi-medicated for the disease itself and other 
accompanying diseases, e.g. hypertension, diabetes, hyperlipidemia, etc. The lack of safe alternatives 
and the results of clinical studies that have not identified any significant side effects or overdoses of 
CS (Hathcock and Shao, 2007), makes this drug a one of the safest drugs for osteoarthritis. 
 The benefit of chondroitin sulfate in patients with osteoarthritis is likely the result of a number 
of effects including its anti-inflammatory activity, the stimulation of the synthesis of proteoglycans 
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and hyaluronic acid, and the decrease in catabolic activity of chondrocytes inhibiting the synthesis 
of proteolytic enzymes, nitric oxide and other substances that contribute to damage cartilage matrix 
and cause death of articular chondrocytes. A recent review summarizes data from relevant reports 
describing the biochemical basis of the effect of chondroitin sulfate on osteoarthritis articular 
tissues (Monfort et al., 2007). The rationale behind the use of chondroitin sulfate is based on the 
belief that osteoarthritis is associated with a local deficiency in some natural substances, including 
chondroitin sulfate. 
Recently, new mechanisms of action have been described for chondroitin sulfate. In an in vitro 
study, chondroitin sulfate reduced the IL-1β-induced nuclear factor-kB (Nf-kB) translocation in 
chondrocytes (Jomphe et al., 2007). In addition, chondroitin sulfate has recently shown a positive 
effect on osteoarthritic structural changes occurred in the subchondral bone (Tat et al., 2007). 
Since CS is taken by the patients for long periods of time, the questions are what does CS do on 
baseline CYP isoforms and, by the nature of its anti-inflammatory effect, does CS prevents the down-
regulation of CYP isoforms during an inflammatory reaction? 
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II. HYPOTHESIS AND 
STUDY OBJECTIVE 
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Patients with infectious and/or inflammatory diseases may present transient decreases in the 
activity of the mixed function oxidase system (Chang et al., 1978; Sonne et al., 1985). In animals, a 
turpentine-induced inflammatory reaction reduces the activity of selected isoforms of the cytochrome 
P450 (Letarte & du Souich, 1984; Wright & Morgan, 1990; Parent et al., 1992). There is limited 
information about the mechanism of action underlying the changes in CYP activity and expression 
provoked by an inflammatory reaction secondary to the injection of turpentine (Barakat et al., 2001); 
although it is known that cytokines like IL-6 and IL-1β are the primary serum mediators and that the 
mechanism of action implies a pretranscriptional phenomena (Bleau et al., 2003). It is also known 
that IL-1β activates the nuclear translocation of NF-κB which binds to negative regulatory elements 
of cytochrome P450 genes impeding the transcription of the gene (Iber et al., 2000). On the other 
hand, chondroitin sulfate (CS) elicits an anti-inflammatory effect by a mechanism not fully 
understood. CS prevents IL-1β-induced p38MAPK and Erk1/2 phosphorylation and diminishes NF-
κB nuclear translocation (Jomphe et al., 2008). 
These observations led us to hypothesize that chronic intake of CS could prevent the effects of 
turpentine-induced inflammatory reaction on cytochrome P450 expression and activity. 
The project’s objective was to assess the effect of CS on the activity and expression of hepatic 
CYP in rabbits in vivo with and without a turpentine-induced inflammatory reaction, and secondly to 
assess the effect of CS on the activity and expression of hepatic CYP in vitro, along with the three 
sulphated disaccharides of CS (4S, 6S and 4,6S). The primary objective of this study is an 
exploratory one. 
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III. MATERIALS AND 
METHODS 
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EXPERIMENTAL PROTOCOL 
 
The dose of chondroitin sulfate used in humans for the treatment of osteoarthritis is 800-1,200 mg 
orally per day or 11 to 17 mg/kg. The dose of CS administered to the rabbits was approximately 20 
mg/kg/day (± 5 mg/kg/day) dissolved in the water to be drunk along the day.  The effect of chronic 
intake of CS on the cytochrome P450 was tested with two models, control rabbits and in rabbits with an 
inflammatory reaction.  Seven groups of five rabbits were used: one group was kept for 30 days in the 
animal facilities and used as control; three groups of normal rabbits were used to assess the effect of CS 
on cytochrome P450, one without CS and two receiving orally 20 mg/kg/day CS for 20 and 30 days. 
The remaining three groups received turpentine s.c. generating an aseptic inflammatory reaction (AIR) 
48 h before their sacrifice, e.g. at days -2, 18 and 28, and were exposed to CS for 0, 20 or 30 days, 
respectively. Rabbits of all groups were sacrificed and the liver was removed to assess the activity, 
protein content and mRNA of CYP1A2, 3A6 and NADPH-reductase (Figure 8). 
Before the sacrifice of the rabbits, blood was withdrawn (15 ml). Serum was obtained by leaving 
the blood at room temperature for at least 2 h, followed by centrifugation at 2500 rpm for 5 minutes. 
The serum was employed to assess the seromucoids according to the method described elsewhere 
(Parent et al., 1992).     
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Figure 8. Protocol representation 
 
 
 In vivo studies 
 
Male New Zeeland rabbits (2-2.3 kg) (Charles River, St-Constant, Qc, Canada) were housed in 
separate cages and fed water and chow ad libitum for at least seven days before experiments started. 
Seven groups of five rabbits each were used, of which three groups were controls and the remaining 
four received dissolved in the drinking water 20 mg/kg/day of CS orally for 20 or 30 days. Two of 
the control groups were used to assess the effect of the inflammatory reaction on the cytochrome 
P450; to this purpose, the rabbits of one control group had an aseptic inflammatory reaction caused 
by the subcutaneous (s.c.) injection of turpentine (volume injected 5 ml distributed at four sites of the 
back), and were sacrificed 48 h later; the rabbits of the second control group received saline s.c. and 
were sacrificed 48 h later (Figure 8.). Finally, the rabbits of the third control group were simply kept 
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in the animal facilities for 30 days to assess the effect of age and environment on the cytochrome 
P450. Of the four groups of rabbits receiving CS, two were exposed to CS for 20 days and two for 30 
days. The rabbits of one group receiving CS for 20 days and one group receiving CS for 30 days received 
turpentine s.c. at day 18 and at day 28, respectively, while the rabbits of the remaining two groups exposed 
to CS received saline s.c., and all rabbits were sacrificed  two days later, e.g. at days 20 or 30. 
Forty-eight hours after the injection of turpentine or saline, a blood sample (15 ml) was 
withdrawn from the rabbit with a sterile Vacutainer Brand SST (Becton Dickinson, Mississauga, 
Ont., Canada). The severity of the inflammatory reaction was assessed by taking the rectal 
temperature and by measuring the concentration of seromucoids (Parent et al., 1992). All 
experiments were conducted according to the Canadian Council on Animal Care guidelines for use of 
laboratory animals and protocols approved by the Comité de déontologie de l’expérimentation 
animale of Université de Montréal. 
 
Hepatocyte isolation and culture conditions 
 
 
Male rabbits were housed in separate cages and fed water and chow ad libitum for at least 7 days 
before experiments started. The inflammatory reaction was provoked by local subcutaneous 
injections of turpentine distributed at four sites of the back of the rabbits (total volume injected 5 ml). 
The severity of the inflammatory reaction was assessed by taking the rectal temperature and by 
measuring the concentration of seromucoids (Parent et all., 1992).  
Isolation and culture of primary rabbit hepatocytes was conducted according to the two-step liver 
perfusion method described by Seglen (1976), with minor modifications (El-Kadi et al., 1997). 
The rabbits were anesthetised with 30 mg/kg of sodium pentobarbital. After a laparotomy, the 
cava and portal veins were cannulated; through the portal vein, the liver was perfused with 800 ml of 
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a solution containing 115 mM NaCl, 5 mM KCl, 1 mM KH2PO4, 25 mM HEPES, 0.5 mM EGTA, 
5.5 mM glucose and 0.067 mg/ml heparin, to clear blood from the liver. Thereafter, the liver was 
perfused with a solution containing 0.013% collagenase, 1 mM CaCl2 and 0.25 mM trypsin inhibitor, 
until the digestion of liver was completed (the time will vary with the size of the liver). Complete 
digestion was indicated by softening and enlargement of the tissue.  
When the perfusion was completed, the liver was removed and placed in a dish; using tissue 
scissors the capsule was gently thorn and the cells were separated in 100 ml medium containing 
0.013% collagenase, 1 mM CaCl2 and 0.25 mM trypsin inhibitor, 1 ml William medium E (WME) to 
which was added 10 % calf serum, 1% streptomycin/penicillin and 1.2 µM MgSO4 at 37o C. The 
digested material was then filtered through a nylon membrane of 230 µm, followed by a second 
filtration through a nylon membrane of 80 µm.  
The resulting cell suspension was then divided equally into four sterile centrifuge tubes of 50 ml 
on the ice, adding WME up to 50 ml. The cell suspension was washed by low-speed centrifugation 
(100 g for 5 min). The supernatant was discarded and cells were gently resuspended in approximately 
20 – 30 ml WME. This stage was repeated three times.  
Harvested cells were centrifuged on isodensity Percoll to isolate viable liver cells (over 95% 
viability as assessed by tryptan blue exclusion). Hepatocytes (3 x 106 in 3 ml of William’s medium E 
supplemented with 10% calf serum) were plated in 12-well plastic culture plates (Corning; Fisher, 
Mississauga, Canada) coated with type I rat tail collagen. Cell culture was conducted under sterile 
conditions and maintained at 37o C in a humidified atmosphere containing 95% air and 5% CO2. The 
medium was changed 2h after plating, and thereafter the hepatocytes were incubated for an additional 
4 hours before onset of the experiments.  
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In vitro studies 
 
 
 The objective of this series of experiments was to explore whether incubation of various 
concentrations of CS and its disaccharides with hepatocytes for 48 hours affected the activity and 
expression of CYP1A2, CYP3A6 and NADPH cytochrome P450 reductase (CPR). 
 Plated hepatocytes were kept for one hour at 37ºC in a humidified atmosphere of 5% CO2 and 
95% air before their culture medium was changed and four different concentration of CS and its three 
disaccharides were added as follows: 
¾ CS: 50, 100, 200, 450 µg/ml 
¾ 4S-disaccharide: 10, 20, 40, 80 µg/ml  
¾ 6S-disaccharide: 10, 20, 40, 80 µg/ml  
¾ 4,6S-disaccharide: 10, 20, 40, 80 µg/ml  
The hepatocytes were allowed up to 48 hours of incubation before assessing the activity and the 
amount of CYP1A2, CYP3A6 and NADPH-reductase. Proteins were assessed by Western blot 
analysis.  
The chondroitin sulfate used in the present study is purified chondroitin 4&6 sulfate of bovine 
origin (Volpi and Maccari, 2005), the same was used in clinical studies (Uebelhart and col., 2004; 
Clegg and col., 2006). The chondroitin sulfate used may contain disulfated disaccharides that are not 
detectable or present in a minor concentrations (<0.1%). 
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 Measure of Oxide Nitric (NO˙) from hepatocyte culture supernatant 
 
 
Nitric oxide was determined by measuring nitrite and nitrate in the culture media using a 
colorimetric method based on the Griess reaction (Nims et all., 1996).  
To reduce nitrate to nitrite, samples were incubated at 37o C in the presence of 0.1 U/ml nitrate 
reductase, 50 µM NADPH and 5 µM FAD. Following nitrate reduction, to avoid any interference 
with the determination of nitrite, NADPH was oxidized by incubating the samples with 10 U/ml 
lactate dehydrogenase and 10 mM sodium pyruvate for 5 min at 37o C. The concentration of nitrite 
was assumed to reflect that of nitric oxide and the results are expressed as concentration of NO˙ 
relative to total mg proteins.  
 
Quantification of CYP3A6 activity 
 
The activity of CYP3A6 was determined by measuring the ability of the hepatocytes to convert 
3,4-difluorobenxyloxy-5,5-dimethyl-4-(4-methylsulfonyl phenyl)-(5H)-furan-2-one (DFB), a CYP3A 
probe, to 3-hydroxy-4-(4-methylsulfonyl phenyl)-(5H)-furan-2-one (DFH), its fluorescent metabolite 
(Chauret et all., 1992). After 4 hours of incubation, the growth media was removed and the cellular 
layer was rinsed twice with 300 µl of Krebs solution (9.6 g/L Krebs, 2.5 mM CaCl2·2H2O, 25 mM 
sodium bicarbonate, 12.5 mM HEPES of pH 7.4). Briefly, 60 µM of DFB were incubated for 20 min 
with the hepatocytes, and then 100 µl of the supernatant was transferred to a microtiter plate and 
quenched with an equal volume of acetonitrile containing 40% Tris buffer (0.05 M). The 
fluorescence metabolite DFH was measured at excitation and emission wavelengths of 360 and 440 
nm, respectively, using a fluorescent plate reader (Victor2, 1420 Multilabel Counter, PerkinElmer 
Wallac, Gaithersburg, Maryland, USA). 
 
71 
 
Quantification of CYP1A2 activity 
 
 
The activity of CYP1A2 was determined by measuring the methoxyresorufin O-demethylation 
(MROD) to resorufin in intact cells, as described by Van Vleet et al. (2002). Growth media was 
removed and cells washed twice with 300 µl of WME. After removal of WME, 3.3 µM 
methoxyresorufin in 300 µl of WME was added to the wells containing the hepatocytes and 
incubated for 10 min at 37o C. Thereafter, 100 µl of supernatant was added to 100 µl of a solution of 
perchloric acid/glycine and 5.4% K2CO3 (2:1, v/v). Resorufin production was measured 
fluorimetrically at excitation and emission wavelengths of 530 and 584 nm respectively, with a 
fluorescent plate reader (Victor2, 1420 Multilabel Counter, PerkinElmer Wallac, Gaithersburg, 
Maryland, USA). 
 
NADPH-Reductase Assay 
 
 
This assay measures the reduction of cytochrome c by NADPH-cytochrome c reductase in the 
presence of NADPH. The absorption spectrum of cytochrome c changes with its oxidation/reduction 
state. Upon reduction, a sharp absorption peak is observed at 550 nm. The reduction of cytochrome c 
is monitored by the increase of cytochrome c absorbance at 550 nm. The activity is measured with a 
spectrophotometer, using Soresen’s phosphate buffer at room temperature; 1-4 milliunits of enzyme 
are added per assay. Samples from rabbit hepatocytes are assayed in the presence of potassium 
cyanide. The activity of the samples assayed is calculated using the following unit definition: one 
unit will reduce 1.0 µmole of oxidized cytochrome c in the presence of 100 µM NADPH per minute 
at pH 7.8 at 25ºC (Masters et Kamin, 1967). 
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∆A550/min = ∆Asample - ∆Ablank 
dil = the dilution factor of the original enzyme sample 
Enzvol = volume of the enzyme sample (ml) 
21.1 = extinction coefficient (εmM) for reduced cytochrome c 
1.1 = reaction volume (ml) 
 
BCA Protein Assay 
 
 
Hepatocyte monolayers were frozen under liquid N2, and then stored at -80oC, for a latter 
utilisation. FOZ- buffer (with 1:1000 leupeptine, 1:100 sodium ortho-vandate and 1:1000 
phenylmethanesulphonylfluoride) is added to six-well plates containing the hepatocytes. After 30 
minutes incubation, the cells are scraped off and transferred in tubes for centrifugation (10 min at 
13,000 rpm). The supernatant is stored at -80oC or it is used further for protein measurement, which 
is done by BCA Protein Assay as it follows: 
1. Supernatant is diluted 1/70 
2. Serial dilution for standard curve was performed using bovine serum albumin (BSA) 
3. 25 µl of each standard and each sample was added to a 96-well microplate. Samples were 
assessed in triplicata. 
4. Working reagent is prepared using a ratio of 1:20 (Reagent A: Reagent B) 
5. 200 µl of working reagent was added to each well. 
6. The microplate was placed in an incubator for 30 minutes at 37 oC.  
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7. Absorbance of each well was read with a microplate reader. 
8. Amount of protein in each well was calculated by plotting a standard curve using Excel 
software. 
 
Measure of the expression of CYP1A2, CYP3A6 proteins, and NADPH-
reductase 
 
 
The amount of CYP1A2 and CYP3A6 proteins in hepatocytes incubated for 4 hours was 
assessed by Western blot analysis. Proteins (60 µg) were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (7.5% polyacrylamide) at 120 V. Proteins were 
electrophoretically transferred to a nitro-cellulose membrane using a semidry transfer process (Bio-
Rad, Hercules, CA, USA).  
CYP1A2 was detected with a polyclonal anti-rabbit CYP1A1/2 antibody (1:100) incubated for 
16 hours, and then visualized with an alkaline phosphatase conjugated secondary goat antibody 
(1:16666) using blue tetrazolium as the substrate.  
CYP3A6 protein was detected with a monoclonal anti-rat CYP3A1 antibody (1:2000), with a 
cross-reactivity to rabbit CYP3A6, incubated for 16 hours; thereafter, an incubation of 1 hour 
follows with a horse-radish peroxidase-conjugated secondary antibody (HRP) diluted at 1:8000. 
Chemiluminescence was visualized by autoradiography with the kit ECL advance (GE 
Healthcare, Canada).  
NADPH-reductase was detected with a monoclonal anti-mouse NADPH-reductase antibody 
(1:5000) incubated for 16 hours; thereafter, an incubation of 1 hour follows with a horse-radish 
peroxidase-conjugated secondary antibody (HRP) diluted 1:2000. Chemiluminescence was visualized 
by autoradiography with the kit ECL advance (GE Healthcare, Canada). 
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In each gel, 50 µg of proteins extracted from the same batch of HCONT, with constant amounts 
of CYP1A2, CYP3A6 and NADPH-reductase were used as reference proteins. The assay was 
linear in the range of protein amounts assessed under the present experimental conditions. The 
intensities of the bands were measured with the software Un-Scan-It-Gel (Silk Scientific Inc., 
Orem, UT, USA), and the results are presented as the ratio of the experimental samples to the 
respective reference protein. 
  
NF-κB nuclear translocation   
 
 
The effect of CS on the nuclear translocation of NF-κB was assessed with hepatocytes cultured 
for 48 hr in 12-well plates containing 12 glass coverslips. Hepatocytes were incubated overnight with 
250 µl of rabbit anti-p65 NF-κB antibody diluted 1:250. Secondary antibodies included the Alexa 
488 goat anti-rabbit IgG (H + L) antibody 1:250 to visualize NF-κB. To visualize the nuclei, the glass 
coverslips were incubated with the blue fluorescent probe 4',6-diamidino-2-phenylindole (DAPI), 
1 µl/ml, for 15 min., after which they were washed with water and mounted on slides in Vectashield 
for subsequent observation by epifluorescence microscopy, on a Nikon Eclipse TE-200 inverted 
microscope. Images of immunofluorescent labelling were acquired using a Hamamatsu Orca-II 
digital cooled CCD camera and an Inovision workstation using the Isee software (Inovision 
Corporation, Raleigh, NC, USA). 
Nuclear translocation of NF-κB, determined by immunofluorescence, was expressed as the ratio 
between the numbers of nuclei stained with secondary goat anti-rabbit IgG anti p65 NF-κB 
antibodies over the total number of nuclei marked with the DAPI probe. In each experiment, a 
minimum of five fields were examined and assessed, and the average value recorded. 
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Purification of total RNA from hepatocytes 
 
 
The protocol for purification of total RNA was done according to RNeasy Mini Kit Qiagen bench 
protocol. Hepatocytes were plated in 6-well plastic culture plates (Corning; Fisher, Mississauga, 
Canada) coated with type I rat tail collagen. Cell culture was conducted under sterile conditions at 37o C 
in a humidified atmosphere containing 95% air and 5% CO2 for 4h. After incubation, the plates were 
washed with 500 µl of PBS 1X, then trypsin-EDTA 0,25% was added to detach the cells from plate, 
and medium (containing serum to inactivate the trypsin) was added. A centrifugation was performed 
for 5 min at 300 x g to recover the cells in the pellet, and the supernatant was carefully removed by 
aspiration. The pellet was kept at -80 ºC, for a later use or was used directly in the procedure. Β-
mercaptoethanol (β-ME) was added to Buffer RLT before use, to produce the lysis. The lysate was 
homogenized by passing it at least 5 times through a blunt 20-gauge needle (0.9 mm diameter) fitted to 
an RNase-free syringe; 1 volume of 70% ethanol was added to the homogenized lysate and mixed well 
by pipetting. At this time DNase digestion was performed, for eliminating genomic DNA 
contamination. The whole volume was transferred to an RNeasy spin column and centrifuged for 30 s 
at 13,000 rpm; the flow-through was discarded. Next, RW1 buffer was added to the RNeasy spin 
column followed by a centrifugation at 13,000 rpm for 30s to wash the spin column membrane. Five 
hundred µl Buffer RPE was added to the RNeasy spin column and centrifuged for 30 s at 13,000 rpm to 
wash the spin column membrane; the flow-through was discarded. This procedure was repeated twice. 
To elute the RNA, the RNeasy spin column was placed in a new 1.5 ml collection tube, and 20-25 
µl RNase-free water was added directly to the spin column membrane. The quality of the RNA 
samples was determined by electrophoresis through agarose gels and staining with ethidium 
bromide to visualize RNA under ultraviolet light. The samples were kept to -80ºC until the next 
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utilisation. Real-time RT-PCR was performed by the Genomic platform of the IRIC to quantify 
mRNA expression in hepatocytes. 
Briefly, total RNA was isolated using Trizol according to manufacturer’s protocol (RNeasy Mini 
Kit Qiagen bench protocol). RNA was treated with DneaseI (Invitrogen) before cDNA synthesis. 
Reverse transcription of total RNA was performed using the MMLV-RT and random hexamers 
according to manufacturer’s protocol (Invitrogen).  
Gene expression levels (CYP3A6 and NADPH P450 reductase) were measured by custom primers 
and TaqMan probes using the online version of PrimerQuest software 
(http://scitools.idtdna.com/Primerquest/). Default parameters for real-time PCR were used to select the 
best primers and probes. In order to amplify only the cDNA, primers were located in different exons or 
in the splicing junction between two exons. PCR reactions were performed using 2 µL of cDNA 
samples (10-40 ng), 5 µL of the TaqMan PCR Master Mix (Applied Biosystems), 10 pmol of each 
primer, and 5 pmol of the TaqMan probe in a total volume of 10 µL.  
The ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) was used to detect 
the amplification level and was programmed to an initial step of 10 minutes of 95ºC, followed by 50 
cycles of 15 seconds at 95ºC and 1 minute at 60ºC. All reactions were run in triplicate and the average 
values were used for quantification. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as 
endogenous control. The relative quantification of target genes was determined by using the ∆∆CT 
method. Briefly, the Ct (threshold cycle) values of target genes were normalized to the endogenous 
control gene (GAPDH) (∆CT = Cttarget - CtGAPDH) and compared with a calibrator (control Sca+Lin-
cells): ∆∆CT = ∆CtSample – ∆CtCalibrator. Relative expression (RQ) was calculated using the Sequence 
Detection System (SDS) 2.2.2 software (Applied Biosystems) and the formula RQ = 2-∆∆CT. 
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Oligos Sequence 
 
NADPH-Cyt P-450 reductase 
Primer a = ACAAGACCTACGAGCACTTCAACG 
Primer b = AAGTCCTCCTCCAGGTTTGCATCA 
Probe = AGCGCATCTTCGAGCTGGGCAT 
CYP3A6 
Primer A = AGCACTGGACTGAGCCTGATGAAT 
Primer B = AACCTCATGCCAAGGCAATTTCGG 
Probe = CCGCCCTGAAAGGTTCAGTAAGAAGA 
GAPDH 
Primer A = GGCATTGCCCTCAATGACCACTTT 
Primer B = GTGGTTTGAGGGCTCTTACTCCTT 
Probe = ACGAATTTGGCTACAGCAACAGGGTGGT 
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Statistical analysis 
 
 
All results are reported as means ± S.E. The comparison of the results from the various 
experimental groups and their corresponding controls was carried out using a two-way analysis of 
variance (ANOVA) followed by “Holm-Sidak Method”. The differences were considered significant 
when P < 0.05. The analysis was done by the means of SigmaStat software 3.11.  
 
Materials 
 
 
Percoll gradient, William’s medium E, calf serum, type I rat tail collagen, trypsin inhibitor, 
NaCl, KCl, KH2PO4, EDTA, EGTA, glucose, heparin, N-2-hydroxyethylpiperazine-n '-2-
ethanesulfonic acid, pH 7.2 (HEPES), trypsin inhibitor, glycine, T 
RIS tampon, sulphanilamide, N-NEDA, methoxyresorufine, blue tetrazolium, sodium orthovanadate, 
Krebs-Henseleit, and Temed were purchased from Sigma (Oakville, Ontario, Canada). NaCl, KCl, 
KH2PO4, CaCl2, sodium pyruvate, acetonitrile, methanol, DMSO and 6, 24 and 96 well-plates were 
purchased from Fisher Scientific Canada (Ottawa, ON, Canada). The foetal calf serum (FCS) and 
penicillin/streptomycin were purchased from Gibco (Invitrogen cell culture, Burlington, ON, 
Canada). The type IV collagenase was purchased from Worthington Biochemicals (Lakewood, NJ, 
USA). The turpentine was purchased from Recochem (Montréal, QC, Canada).  The DFB and DFH 
were generously donated by Merck Frost Canada (Kirkland, QC, Canada). Monoclonal anti-rat CYP 
3A1 antibody and polyclonal anti-rabbit CYP 1A1/2 antibody was purchased from Oxford 
Biochemical Research (Oxford, MI, USA). Monoclonal anti-mouse NADPH-reductase antibody and 
the horse-radish peroxidase-conjugated secondary antibody (HRP) were obtained from Santa Cruz 
Biotechnologies (Santa Cruz, CA, USA). Nitrate reductase and lactate dehydrogenase were 
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purchased from Roche Diagnostics (Mannheim, Germany). Rabbit anti-p65 NF-κB antibody was 
acquired from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Chondroitin sulfate and its 
derived disaccharides were provided by Bioibérica (Barcelona, Spain).  
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IV. RESULTS 
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CYTOCHROME P450 AND NADPH-REDUCTASE ACTIVITY  
 
 
1 - Effect of an inflammatory reaction on CYP1A2, CYP3A6 and NADPH-
reductase activity 
 
The first step of this study was to determine if the inflammatory reaction would cause the down-
regulation of the cytochrome P450 isoforms CYP1A2 and CYP3A6, and would the effect NADPH-
reductase activity. The activity of CYP1A2, CYP3A6 and NADPH-reductase in hepatocytes obtained 
from the rabbits with an aseptic inflammatory reaction was compared with those activities from 
control rabbits. Results are reported as arbitrary units of activity divided by the amount of proteins 
(mg). As indicated in table 1, the activity of CYP1A2 decreased by 56% (p<0.05), and the activity of 
CYP3A6 was reduced by 63% (p<0.05); the inflammatory reaction did not change the activity of 
NADPH-reductase. 
 
Activity 
(Arbitrary units/mg protein) 
Hcont Hinfla 
NADPH-reductase  33 ± 3 
(n=5) 
29 ± 7 
(n=5) 
CYP1A2  633 ±131 
(n=5) 
276 ± 77* 
(n=5) 
CYP3A6  1565 ± 263  
(n=5) 
570 ± 174* 
(n=5) 
 
 
Table 1.  NADPH-reductase, CYP1A2, CYP3A6 activity assessed in hepatocytes from control rabbits (Hcont) 
and in hepatocytes from rabbits with an inflammatory reaction (Hinfla). *p <0,05 compared with Hcont 
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2 - Effect of the administration of CS for 20 days on the activity of CYP1A2, 
CYP3A6 and NADPH-reductase 
 
In the control rabbits receiving CS for 20 days, the activity of hepatic CYP1A2 tended to 
increase. On the other hand, following 20 days of intake of CS, the activities of CYP3A6 and 
NADPH-reductase tended to decrease (p>0.05). 
Treatment of rabbits with chondroitin sulfate for 20 days did not prevent the reduction in activity 
of CYP1A2 and CYP3A6 produced by the inflammatory reaction.  
As indicated in table 2, the inflammatory reaction diminished the activity of CYP1A2 by 73% 
(p<0.05), and that of CYP3A6 by 67% (p<0.05). In rabbits with the inflammatory reaction, intake of 
CS for 20 days did not affect the activity of NADPH-reductase.  
 
Activity 
(Arbitrary units/mg protein) 
HcontCS20days HinflaCS20days 
NADPH-reductase  23 ± 3 
(n=5) 
20 ± 2 
(n=5) 
CYP1A2  920 ±171 
(n=5) 
246 ± 90* 
(n=5) 
CYP3A6  1030 ± 270  
(n=5) 
340 ± 65* 
(n=5) 
 
 
Table 2. NADPH-reductase, CYP1A2, CYP3A6 activity assessed in the hepatocytes from control rabbits 
(Hcont) and in the hepatocytes from rabbits with an inflammatory reaction (Hinfla) following the 
administration of CS for 20 days. *p <0,05 compared with Hcont 
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3- Effect of the administration of CS for 30 days on the activity of CYP1A2, 
CYP3A6 and NADPH-reductase 
 
Since the intake of CS for 20 days did not affect the activity of the isoforms of the CYP, it was 
of interest to document whether a prolonged intake of CS, eg. for 30 days, would modify the effect of 
the inflammatory reaction.  
In control rabbits, after the intake of CS for 30 days, the activity of CYP1A2 was not modified 
although the activity of CYP3A6 tended to decrease (p>0.05). In rabbits with the inflammatory 
reaction, the intake of CS for 30 days did not prevent the decrease of the activity of CYP1A2 and 
CYP3A6. The activity of NADPH-reductase was not affected by the experimental conditions. As 
indicated in table 3, in rabbits administered CS for 30 days, the inflammatory reaction decreased the 
activity of CYP1A2 by 48% (p<0.05) and that of CYP3A6 80% (p<0.05).  
 
Activity 
(Arbitrary units/mg protein) 
HcontCS30days HinflaCS30days 
NADPH-reductase  18 ± 1 
(n=5) 
15 ± 2 
(n=5) 
CYP1A2  410 ±37 
(n=5) 
213 ± 43* 
(n=5) 
CYP3A6  827 ± 112  
(n=5) 
159 ± 30* 
(n=5) 
 
 
Table 3. NADPH-reductase, CYP1A2, CYP3A6 activity assessed in hepatocytes from control rabbits (Hcont) 
and in hepatocytes from rabbits with an inflammatory reaction (Hinfla) following the administration of CS for 
30 days. *p <0,05 compared with Hcont 
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There is no significant change in activity of NADPH-reductase due to inflammation, when 
compared with control rabbits after 30 days of CS intake. Contrary there is a significant decrease of 
this activity when compared with control rabbits with no CS intake. It is important to observe that 
there is a tendency to decrease as a function of time, for the activity of NADPH-reductase and 
CYP3A6, and CS does not exibit a protective role. 
 
4A - Effect of 30 days stay in the animal facilities on CYP1A2, CYP3A6 and 
NADPH-reductase activities 
 
Since in the the previous two study groups, the rabbits were kept for 30 days in the animal 
facilities, a control group of rabbits kept for 30 days in the animal facilities without any other 
intervention was necessary. Therefore, the effect of 30 days in the animal facilities on the activities of 
CYP1A2, CYP3A6 and NADPH-reductase was assessed.  
The activity of CYP1A2 for the group of rabbits without CS intake, kept 30 days in the animal 
facilities is not significantly decreased when compare with control 0 days CS. The only difference 
observed is the significant increase in the activity of CYP1A2 for control group with 20 days intake 
of CS, but overall the activity of CYP1A2 does not seams to be influenced by the time the rabbits 
spent in the animal facilities (figure 9-A). 
The activity of CYP3A6 remains depressed as a function of time. The group of rabbits kept in 
animal facilities for 30 days register the lowest activity of CYP3A6, but comparable with that of 
control group with 30 days of CS intake (figure 9-B). 
The activity of NADPH-reductase shows a significant decrease for group of rabbits kept for 30 
days in animal facilities, when compared with control group 0 days, but is still comparable with that 
of control group 30 days CS (figure 9-C). 
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Figure 9. (A) CYP1A2 activity in hepatocytes from rabbits pre-treated with CS for 
20 and 30 days, with or without an inflammatory reaction. 
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(B) CYP3A6 activity in hepatocytes from rabbits pre-treated with CS for 20 
and 30 days, with or without an inflammatory reaction. 
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(C) NADPH-reductase activity in hepatocytes from rabbits pre-treated with 
CS for 0, 20 and 30 days, with or without an inflammatory reaction. 
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CYTOCHROME P450 AND NADPH-REDUCTASE EXPRESSION 
 
 
 
1- Effect of the inflammatory reaction on the expression of CYP1A2, 
CYP3A6 and NADPH-reductase 
 
Proteins from group of rabbits without CS administration, with and without an AIR, were 
subjected to Western blotting analyses, to confirm the differential expression of CYPs and 
NADPH-reductase (Figure 10). Compared with control rabbits at Day 0, CYP1A2 protein 
expression decreased by 0.69 ± 0.150 (p<0.05) and CYP3A6 protein expression decreased 
significantly by 0.78 ± 0.07 (p<0.05) 48 hours after the production of turpentine-induced 
inflammatory reaction. There was no change in the protein expression of NADPH-reductase 
following an aseptic inflammatory reaction.  
 
 
2- Effect of the administration of CS for 20 days, on the expression of 
CYP1A2, CYP3A6 and NADPH-reductase 
 
Proteins from gruop of rabbits with CS intake for 20 days, with and without and AIR were 
subjected to Western blotting analyses, to confirm the differential expression of CYPs and NADPH-
reductase (Figure 10). CS administered for 20 days to the control group of rabbits prevents the time-
dependent decrease of CYP3A6 protein expression, when compared with control group without CS 
intake (figure 11-A). Contrary, it does not exhibit the same effect on the CYP1A2 protein expression, 
since it is significantly decreased when compare with control group 0 days CS. NADPH-protein 
expression shows no significant diference for group of rabbits with 20 days of CS intake. 
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The administration of CS for 20 days before producing the turpentine-induced inflammatory 
reaction did not prevent the decrease in protein expression of CYP1A2 (0.33± 0.06). On the other 
hand, after 20 days of CS intake, decrease in CYP3A6 protein expression produced by the aseptic 
inflammation was less apparent, but still lower (p<0.05) than that observed in control rabbits at 
Day 0 (0.55 ± 0.06). The protein expression of NADPH-reductase showed no change after 20 days 
of CS intake. 
 
3- Effect of the administration of CS for 30 days, on the expression of 
CYP1A2, CYP3A6 and NADPH-reductase 
 
Proteins from group of rabbits with CS intake for 30 days, with and without and AIR were also, 
subjected to Western blotting analyses, to confirm the differential expression (Figure 10). CYP1A2 
protein expression is significantly decreased in group of rabbits with 30 days of CS intake, when 
compared with control group without CS intake (figure 11-B). Contrary, the administration of CS 
seems to stabilize CYP3A6 protein expression at levels comparable with control group without CS 
intake (figure 11-A). There is no decrease of NADPH-reductase protein expression in the group of 
rabbits with 30 days of CS intake, when compared with control group without CS intake (figure 11-
C). The administration of CS for 28 days before producing the turpentine-induced inflammatory 
reaction and for the next 48 hours did not prevent the decrease in protein expression of CYP1A2 
(figure 11-B). Interestingly, after 30 days of CS intake, CYP3A6 protein expression in rabbits with a 
turpentine-induced inflammatory reaction was similar to the values estimated in control rabbits 
receiving CS for 30 days, e.g. 0.85 ± 0.18 vs 0.88 ± 0.10, respectively. In other words, after 30 days 
of CS, the inflammatory reaction did not diminish CYP3A6 expression (figure 11-A). NADPH-
reductase protein expression showed a step-wise diminution time-dependent that could not be 
prevented by the administration of CS (figure 11-C). 
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Figure 10. Protein expression at O Days, 20 Days and 30 Days for (A) CYP1A2, (B) CYP3A6, (C) NADPH-reductase. 
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4- Effect of 30 days stay in the animal facilities on protein expression  
 
Compared with control rabbits at 0 Days, e.g. after only seven days of acclimatization, the 
protein expression of CYP1A2 in rabbits kept for 30 days in the animal facilities was significantly 
decreased, but similar with that observed at rabbit group with 30 CS intake (figure 11-B). The protein 
expression of CYP3A6 in group of rabbits kept in animal facilities for 30 days is decreased 
significantly when compared with control group without CS or rabbits group with 30 days CS intake 
(figure 11-A).  
The expression of NADPH-reductase did not change as a result of keeping rabbits for 30 days in 
the animal facilities (there is no statistically significant change) (figure 11-C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 11. Effect of the administration of CS for 20 and 30 days on 
(A) CYP3A6 expression in hepatocytes from rabbits with or without an inflammatory reaction
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(B) CYP1A2 expression in hepatocytes from rabbits with or without an inflammatory reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) NADPH-reductase expression in hepatocytes from rabbits with or without an inflammatory reaction. 
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5 - Effect of CS on mRNA of CYP3A6  
 
Contrary with the effect observed on the activity of CYP3A6, but similar with the CYP3A6 
protein expression, the mRNA of CYP3A6 remains stable as result of time (figure 12-A), in group of 
rabbits with 20 days and 30 days of CS without inflammation .  The intake of CS for 20 and 30 days 
does not prevent the decrease of CYP3A6 mRNA in rabbits with aseptic inflammation, though not 
statistically significant because of variability. Data on mRNA of CYP1A2 in not available, due to 
laboratory technical problems. 
In group of rabbits with 20 and 30 days of CS intake the mRNA of NADPH-reductase remains 
similar with that of control rabbits without CS intake (Day 0). In rabbits with turpentine-induce 
inflammatory reaction, the mRNA expression of NADPH-reductase was similar to that estimated in 
control rabbits at Day 0; however, after 20 days of CS intake in rabbits with aseptic inflammation 
mRNA of NADPH-reductase tends to decrease (figure 12-B). In group of rabbits with AIR and 30 
days of CS intake, mRNA of NADPH-reductase tends to further decreased although not statistically 
significant because of variability. 
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Figure 12. (A) CYP3A6 mRNA (expressed as percentage of controls). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) NADPH-reductase mRNA (expressed as percentage of controls). 
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MARKERS OF INFLAMMATION 
 
 
The estimates of seromucoid concentrations in vivo, as well as nitric oxide (NO•) concentrations in 
the supernatant of the 4 hours incubation of rabbit hepatocytes, and NF-κB nuclear translocation in the 
hepatocytes were used as biomarkers of systemic and cellular inflammation and also to evaluate the 
effect of CS on the inflammatory reaction. 
 
1- Seromucoid concentration 
 
At day 0, in control rabbits (n = 5), the concentration of seromucoid was 8.35 ± 1.55 mg/dl, and in 
rabbits with a turpentine-induced inflammatory reaction (n = 5), 48 hours after the injection of 
turpentine, the concentration of seromucoid was tenfold greater (p<0.05 compared with values in 
control rabbits) (Table 4), strongly supporting that the injection of turpentine did produce an 
inflammatory reaction. The administration of CS to control rabbits for 20 (n = 5) or 30 days (n = 5) did 
not influence seromucoid concentrations. Similarly, in rabbits with a turpentine-induced inflammatory 
reaction, after 20 (n = 5) or 30 days (n = 5) of CS intake, seromucoid concentrations remained 
increased and similar to the values determined in rabbits not exposed to CS at day 0.  
Table 4 Seromucoid concentrations in serum from control rabbits and rabbits with a turpentine-induced 
inflammatory reaction (TIIR) at Day 0 and following the intake of approximately 20 mg/kg of chondroitin 
sulfate (CS) for 20 and 30 days. 
  
Seromucoids 
(mg/dl) 
   Day 0 Day 20 + CS Day 30 + CS 
 
Control rabbits 
  
 8.4 ± 1.6 
 
15.1 ± 2.0 
  
 9.5 ± 1.1 
    
Rabbits with TIIR 95.1 ± 5.7* 93.5 ± 2.8* 92.2 ± 9.8* 
    
 
* p<0.05 compared with values of control rabbits 
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2- Nitric oxide concentrations 
 
In the supernatant of hepatocytes harvested from control rabbits, the concentrations of NO• 
tended to increase in groups taking CS for 20 and 30 days (Table 5). Compared with hepatocytes 
from control rabbits at Day 0, the turpentine-induced inflammatory reaction in vivo, increased the 
release of NO• from the hepatocytes in vitro (p<0.05). However, compared with control rabbits 
exposed to CS, in the rabbits with an inflammatory reaction and receiving CS for 20 and 30 days, the 
concentrations of NO• were not increased by the inflammatory reaction. 
 
Table 5 Nitric oxide (NO•) concentrations in hepatocyte’s culture media from control rabbits and rabbits with 
a turpentine-induced inflammatory reaction (TIIR) at Day 0 and following the intake of approximately 20 
mg/kg of chondroitin sulfate (CS) for 20 and 30 days. 
 
 
  
NO• (µM)      Day 0 Day 20 + CS Day 30 + CS 
 
    
    
Control rabbits 1.26 ± 0.18 3.02 ± 0.90 1.68 ± 0.38 
    
Rabbits with TIIR 2.10 ± 0.29* 2.69 ± 1.13 1.48 ± 0.35 
 
 
* p<0.05 compared with values of control rabbits 
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3- Nuclear translocation of NF-κB in hepatocytes 
 
At day 0, around 15% of hepatocytes harvested from control rabbits showed nuclear 
fluorescence, indicating a relatively small NF-κB nuclear translocation (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Fluorescent micrographs representing p65–NF-κB immunopositive nuclei in hepatocytes.  
 (A) in control hepatocytes, nuclei do not show immunofluorescence that is concentrated in the cytoplasma.  
(B) NF-κB immunopositive nuclei activated by inflammation. 
 (C) hepatocytes exposed to chondroitin sulfate for 20 days and inflammation, showing a reduction in nuclei 
immunofluorescence by reference to panel B.  
(D) hepatocytes exposed to chondroitin sulfate for 30 days and inflammation, showing a reduction in nuclei 
immunofluorescence by reference to panel B.  Scales bar in panel A (20 µm). 
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Inflammation + CS 30 daysInflammation + CS 20 days
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In hepatocytes from control rabbits kept for 30 days in the animal facilities, NF-κB nuclear 
translocation was very similar to that observed at Day 0. In the hepatocytes from rabbits with a 
turpentine-induced inflammatory reaction at Day 0, NF-κB nuclear translocation was increased 
fivefold (p<0.05) compared with hepatocytes from control rabbits. In control rabbits, the intake of CS 
for 20 or 30 days did not influence NF-κB nuclear translocation. It is noteworthy that in hepatocytes 
from rabbits with a turpentine-induced inflammatory reaction, CS prevented the increase in NF-κB 
nuclear translocation triggered by the turpentine-induced inflammatory reaction (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  Effect of chondroitin sulphate (CS) on NF-κB nuclear translocation in rabbits hepatocytes, in vivo.
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4- Effect of CS and the ∆di-4S, ∆di-6S and ∆di-4,6S disaccharides on 
CYP1A2, CYP3A6 and NADPH-reductase activity and expression in vitro 
 
 
Incubation of 10, 20, 40, 80 µg/ml of ∆di-4S, ∆di-6S and ∆di-4,6S and 50, 100, 200, 450 µg/ml 
of CS with hepatocytes harvested from control rabbits (n = 3) for 48 hours did not affect the activity 
or the expression of CYP1A2, CYP3A6 and CPR (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Activity and expression of CYP1A2, 3A6, and NADPH-reductase in the presence of different 
concentrations of CS and its disaccharides (∆di-4S, ∆di-6S and ∆di-4,6S), in vitro. 
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V. DISCUSSION 
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Patients with osteoarthritis may receive CS for long periods of time (Zhang et al., 2008). 
Osteoarthritis is frequently associated with other diseases such as obesity, diabetes, hypertension, 
hyperlipidemia and cardiovascular diseases and consequently, the patients with osteoarthritis may be 
poly-medicated (Caterson et al., 2004; Bray and Bellanger, 2006). Therefore, the question whether 
CS may be responsible of drug-drug interactions may be raised. More specifically, since CS is an 
anti-inflammatory agent, two questions can be raised: a) does CS modify the biotransformation of 
drugs under control conditions, and b) does CS modulate the down-regulation of CYP enzymes 
produced by an inflammatory reaction and so may regulate the biotransformation of drugs. 
 
Turpentine-induced inflammatory reaction and markers of inflammation in 
this model 
 
Turpentine oil-induced local irritation is a model of inflammation, which results in the 
recruitment of inflammatory cells and the up-regulation of IL-6 (Sheikh et al., 2006). In the model of 
turpentine-induced inflammatory reaction, IL-6 and in smaller amounts IL-1β are produced locally, at 
the site of turpentine oil injection, released into the blood and responsible forthe acute phase reaction 
triggered in the liver; the acute phase reaction as well as cytokines modulate the activity and 
expression of CYP (Sheikh et al., 2007). Apparently, IL-6 plays an important role in the down-
regulation of several CYP isoforms as demonstrated by a study conducted with IL-6 transgenically 
deficient mice, e.g. the turpentine-induced inflammatory reaction did not depress CYP3A1 in mice 
IL-6-/- (Siewert et al., 2000). In a study done by Bleau et al. (2000) it was reported that IL-6 and IL-
1β are the serum mediators that down-regulate CYP3A6 which are released in vivo by the turpentine-
induced inflammatory reaction in rabbit.  
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Kourylko et al. (2006) showed that the serum of rabbits with a turpentine-induced inflammatory 
reaction, containing IL-6 and IL-1β as serum mediators, down-regulate CYP3A6 through the JAK-
Erk1/2-NF-κB pathway. In aseptic as well as septic inflammatory reacion, NF-κB is a central 
mediator of inflammation, responsible for signals leading to a variety of cellular responses, including 
the induction of pro-inflammatory genes that would finally lead to the release of pro- and anti-
inflammatory cytokines and of diverse enzymes (Figure 16). 
Sterile tissue damage will release heat-shock proteins 60 and 70, and also breakdown products of 
tissue matrix, which will activate pattern recognition receptors (PRRs) and other receptors in immune 
and other tissue cells, as well α5β1-integrin, toll-like receptor (TLR), CD36 and CD44. The activation 
of these receptors will trigger the activation and nuclear translocation of the nuclear factor κB (NF-
κB) in immune cells, epithelial cells of the liver, endothelial cells or locally in the tissue. Nuclear 
translocation of NF-κB will induce the expression of pro- and anti-inflammatory cytokines and of 
enzymes, such as inducible nitric oxide synthase-2 (NOS-2), cyclooxygenase-2 (COX-2) and matrix 
metalloproteinases (MMPs) that will perpetrate the inflammatory reaction (Dumais et al., 2008). 
Because several of these conditions are similar to the inflammatory conditions of osteoarthritis 
(detailed in the Introduction of this thesis), we selected the turpentine-induced inflammatory model to 
study the impact of long term CS administration, focusing on major drug metabolizing enzyme. 
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Figure 16.  Production of an inflammatory reaction.  Infections by means of pathogen-associated molecular 
patterns (PAMPs) activate the pattern recognition receptors (PRRs), including toll-like receptor (TLR), in 
polymorphonuclear cells (PMNs) and other immune cells. 
 
 
 
 
The present study demonstrates that in vivo, in rabbits with a turpentine-induced inflammatory 
reaction, CS prevents the increase in NF-κB nuclear translocation in hepatocytes of rabbits with an 
AIR taking CS for 20 and 30 days. A possible explanation for this finding could be the partial 
inhibition of p38MAPK and to a minor extent Erk1/2 that could finally reduce NF-κB nuclear 
translocation. This explanation is supported by the fact that in vitro, CS diminishes NF-κB nuclear 
translocation in chondrocytes activated by IL-1β (Jomphe et al., 2008). Since NF-κB is activated by 
IL-1β and not by IL-6 (Leeman et al., 2008), we may postulate that even if IL-1β is produced in 
smaller amounts, these low concentrations are enough to trigger the activation of NF-κB in our in 
vivo model of inflammation. 
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Nitric oxide (NO) is induced by an inflammatory stimulation, secondary to the induction of 
inducible nitric oxide synthase (NOS2) in hepatocytes (Liaudet et al., 2000). In our study, NO was 
significantly increased in hepatocytes from the group of rabbits with a turpentine-induced 
inflammatory reaction. NO can bind to the heme of CYP enzymes and inhibit them by reversible or 
irreversible mechanisms (Wink et al., 1993; Vuppugalla and Mehvar, 2004) and therefore, NO may 
be one cause of enzyme inhibition observed in inflammatory states (Veihelmann et al., 1997; 
Kourylko et al., 2006). However, a large number of studies have shown that the down-regulation of 
the majority of hepatic, drug-metabolizing CYP proteins and mRNAs are not affected by deletion of 
the NOS2 gene or by inhibitors of NOS enzymes (Aitken et al., 2006), supporting the notion that NO 
may not be responsible for the down-regulation of CYP enzymes. In other words, there is a NO-
independent pathway responsible for the down-regulation of CYP enzymes. In the present study, the 
production of NO is used as evidence of the presence of a systemic inflammatory reaction, since the 
production of NO could not be entirely accounted for the changes seen in the regulation of CYPs, 
observed in the present study.  
In rabbits with a turpentine-induced inflammatory reaction, the increase of NO is prevented by 
the intake of CS for 20 and 30 days. Moreover, CS prevented NF-κB activation and therefore, we 
might speculate that the expression of NOS-2 should also be reduced (Iovu et al., 2008; Jomphe et 
al., 2008), and consequently the production of NO might be prevented.  
The concentration of seromucoids represents another marker of inflammation used in our study. 
Seromucoids are a crude precipitation fraction of glycosilated proteins such as α1-acid glycoprotein, 
α1-cysteine proteinase inhibitor and hemopexin (Price et al., 1961). Interleukin-6 by regulating the 
synthesis of acute phase proteins in human hepatocytes increases α1-acid glycoprotein levels (Castell 
et al., 1988; Lyoumi et al., 1998; Ling et al., 2004). In the present study, seromucoids concentrations 
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were constantly increased in the presence of turpentine-induced inflammatory reaction and that 
despite the administration of CS for 20 or 30 days. This is in agreement with the belief that the anti-
inflammatory effects of CS are associated to the IL-1β mediated effects (Chan et al., 2005; Jomphe et 
al. 2008; Legendre et al., 2008). We may postulate that CS did not interfere with the regulation of 
seromucoids which are IL-6-dependent and these markers were used only as an evidence of a strong 
systemic inflammation. 
 
Down-regulation of CYP enzymes by TIIR 
 
The aseptic inflammatory reaction reduced CYP3A6 activity by 62% and CYP1A2 activity by 
54%, consequence of a decrease of protein expression of CYP3A6 by 78% and that of CYP1A2 by 
69%. This outcome confirms the results already reported by numerous studies (Chindavijak et al., 
1987; Morgan, 1989; Barakat & du Souich, 1996; El- Kadi et al., 1997; El-Kadi & du Souich, 1998; 
Bleau et al., 2000) showing that in a classic model of inflammation, the administration of turpentine 
causes a significant decrease of several CYP isoforms. 
The CYP isoforms CYP3A6 and CYP1A2 are both down-regulated by the turpentine-induced 
inflammatory reaction even though their regulation is mediated by different signalling pathways. The 
decrease of the expression of CYP enzymes by an inflammatory reaction involves transcriptional and 
post-transcriptional mechanisms. Transcriptional regulation of the expression of CYP enzymes 
depends upon the expression of nuclear receptors, the binding of the nuclear receptors to the DNA-
binding domain, the availability of coactivators/enhancers, and the presence of repressors (Dumais et 
al., 2008). Differences in nuclear receptors, coactivators/enhancers and repressors may thus explain 
the different results observed for the two CYP isoforms characterized in the present study. In 
addition, the cytokine released and activated have a preferential effect on the nuclear receptors 
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modulating each of the two CYP isoforms. For example, IL-1β down-regulates CAR (Assenat et al., 
2004), RXR-α, PPAR-α, PPAR-γ, LXR-α, and the coactivators SRC-1, PGC-1α and PGC-1β (Kim et 
al., 2007), HNF-4 (Krajewski et al., 2007), GR (Liu, 2002), TR (Kwakkel et al., 2007) and, to a 
minor extent, PXR and FXR (Geier et al., 2005). Moreover, IL-1β down-regulates AhR and Arnt 
(Wu et al., 2006). In human hepatocytes, IL-6 rapidly decreases the expression of PXR and CAR 
mRNAs (Teng and Piquette-Miller, 2005), whereas, it does not affect the expression of FXR mRNA 
(Kim et al., 2003). 
 
 
NADPH-reductase in rabbits with a turpentine-induced inflammatory 
reaction in absence and in presence of CS intake 
 
The present study shows that in vivo NADPH-reductase activity decreases as a function of time, 
since the activity of NADPH-reductase of rabbits kept in animal facilities for 30 days is reduced 
significantly when compared with rabbits at 0 day. The addition of CS does not modulate this time-
dependent decrease in activity of NADPH-reductase.  
The protein expression of NADPH-reductase does not share the same tendency as observed with 
the activity, since the protein from the group of rabbits kept for 30 days in animal facilities is not 
decreased. Protein expression of NADPH-reductase is in concordance with mRNA expression that is 
stable over time and is not affected by the administration of CS or by the inflammatory reaction. The 
mechanism underlying the time-dependent decrease in NADPH-reductase activity remains unknown. 
The effect of an inflammatory reaction on the expression and activity of NADPH-reductase, a 
rate-limiting step enzyme of CYP catalytic cycle, remains poorly characterized. The administration 
of lipopolysaccharides (LPS) diminishes NADPH-reductase activity, but in agreement with the 
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present results, turpentine-induced inflammatory reaction does not diminish NADPH-reductase 
activity (Morgan, 1998). 
 
 
 Effect of CS on CYP1A2 and CYP3A6 
 
 The administration of CS for 20 and 30 days elicits a slightly different effect on the two isoforms 
targeted in our study.  
 The expression of CYP1A2 in the group of rabbits kept in the animal facilities for 30 days are 
decreased when compared with control rabbits at Day 0. Moreover, there is a significant decrease in 
the expression of CYP1A2 in the groups of rabbits with a turpentine-induced inflammatory reaction, 
when compared with control groups. The administration of CS for 20 and 30 days did not prevent the 
time-dependent or the inflammatory reaction-induced down-regulation of CYP1A2.  
 Compared with control rabbits at Day 0, the activity of CYP3A6 in control rabbits decreases as a 
function of time when the rabbits are kept for 30 days in the animal facilities. The intake of CS 
partially impeded the time-dependent decrease in activity of CYP3A6 in control rabbits yet 
completely prevented the time-dependent decrease in CYP3A6 expression. 
 The administration of CS for 20 or 30 days before producing the turpentine-induced inflammatory 
reaction did not modulate the inflammatory reaction-dependent decrease in CYP3A6 activity. 
However, after 20 days of CS intake, the turpentine-induced inflammatory reaction-induced decrease 
in CYP3A6 protein expression was less apparent, but still lower (p<0.05) than that observed in 
control rabbits at Day 0. Interestingly, after 30 days of CS intake, in rabbits with a turpentine-induced 
inflammatory reaction CYP3A6 protein expression was similar to the expression estimated in control 
rabbits at Day 0 and control rabbits receiving CS for 30 days. 
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In control rabbits kept for 30 days in the animal facilities, the decrease in CYP3A6 activity might 
be explained in first place, by the decrease in protein expression and secondarily, by the decrease in 
NADPH-reductase activity, that is an obligatory redox partner for it as role of electron transfer and 
conformational changes of CYP3A6 (Yamaguchi et al., 2004; Zhang et al., 2007). 
 
 Effect of CS on CYP3A6 mRNA 
 
Compared with control rabbits at Day 0, in rabbits with the turpentine-induced inflammatory 
reaction, CYP3A6 mRNA decreased by 23%, contrasting with the expression of CYP3A6 that 
decreased by 81%. It is noteworthy that in the group of rabbits with a turpentine-induced 
inflammatory reaction receiving CS for 20 or 30 days CYP3A6 mRNA remained decreased whereas 
CYP3A6 protein expression increased progressively to reach values similar to those observed in 
control rabbits. The mechanisms underlying the increase in protein expression without changes in 
the mRNA might be explained at least in part by a post-transcriptional down-regulation. Several 
mechanisms might be implicated. The first one might be a change in CYP3A6 protein by reactive 
oxygen species or by hydroperoxy free fatty acids and subsequent degradation via the proteasome. 
The second mechanism might be the presence of microRNA that may block the translation of 
CYP3A6 mRNA. Finally, protein O-glycosylation at serine or threonine-residues may reduce 
protein expression. 
A major mechanism for CYP3A6 protein degradation is protein ubiquitination and subsequent 
proteolytic degradation by S26-proteasome (Correia et al., 2005). The ubiquitin proteasome pathway 
involves two discrete and successive processes: the first is tagging of substrates by covalent 
attachment of multiple ubiquitin molecules, and the second is degradation of ubiquitinated proteins 
by the 26S proteasome complex (Jiang and Beaudet, 2004; Karin et al, 2000). Polyubiquitin 
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modification is responsible for targeting proteins for degradation by the proteasome, or to eliminate 
misfolded proteins or to terminate protein function. In addition of that, the attachment of ubiquitin in 
the form of multiple monomers or polymers of different topologies, leads to differences in the 
function of the modified protein through these topological variants (Lang et al., 2008). The tagging 
action of ubiquitin consists of concerted action of several enzymes: E1 (ubiquitin-activating enzyme), 
E2 (ubiquitin carrier or conjugating enzyme) and E3 (ubiquitin-protein ligase) leading to recognition 
by the 26S proteasome, a holoenzyme complex composed of a core 20S catalytic particle and a 19S 
regulatory particle (Jiang et al, 2004; Ravid and Hochstrasser, 2008).  
Ubiquitination and successive protein degradation is modulated by deubiquitination enzymes 
(Amerik and Hochstrasser, 2004) and also, by NF-κB that up-regulates the expression of ubiquitin 
conjugating enzyme, ubiquitin-protein ligase and of the 26S proteasome (Wyke nad Tisdale, 2005; 
Tisdale, 2007). There is evidence that overactivity of ubiquitin-proteasomal system comes in 
response to diverse inflammatory reactions as well as pro-inflammatory cytokines (IFN-γ, IL-1β, IL-
6 and TNF-α) (Dehoux et al., 2003; Li et al., 2003; Maelstrom et al., 2007; Al-Majid and Waters, 
2008). In contrast, deubiquitinating enzymes are decreased by inflammatory reactions and pro-
inflammatory cytokines (Haimerl et al., 2008).    
Zangar and col. (2002) have suggested that the CYP3A4 ubiquitination could occur in the 
absence of CYP3A4 substrates to modulate the amount of protein required. Indeed, CYP3A 
substrates are known to stabilize CYP3A protein in vivo, and in vitro in primary culture rat 
hepatocytes (Watkins et al., 1986; Eliasson et al., 1994; Zangar et al., 2002). On the other hand, 
CYP3A4 ubiquitination occurs in presence of cellular stress, when enzymes generate reactive oxygen 
species and/or reactive metabolic products that attack the CYP heme and/or the protein moiety that 
damage the enzyme structurally and functionally (Correia et al., 2005). 
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In the present study, both conditions are present in rabbits with a turpentine-induced 
inflammatory reaction: the absence of any known substrates for CYP3A6, along with an 
increased hepatic oxidative stress (Proulx and du Souich, 1995; El-Kadi et al., 2000). The 
ubiquitination of CYP3A6 with subsequent degradation by proteasome is a very attractive 
explanation to the present results. 
The mechanism underlying the up-regulation of CYP3A6 by CS might be explained by the fact 
that CS has an antioxidant effect (Canas et al., 2007); however this hypothesis is not supported by the 
fact that even in presence of CYP3A6 up-regulation, the enzyme’s activity did not increase, 
suggesting that the protein remained changed. Alternatively, CS could affect the ubiquitin-
proteasome system through several mechanisms. As was mentioned earlier in this section, NF-κB can 
modulate the ubiquitin-proteasome pathway. In the present study, the nuclear translocation of NF-κB 
is prevented by CS, and as a consequence, CS might have down-regulated intracellular 
concentrations of ubiquitin conjugating enzyme, ubiquitin ligase, and of the 26S proteasome. 
Secondly, CS and other glycosaminoglycans may modulate the ubiquitin-proteasome system 
affecting directly the ubiquitination process. Preliminary evidences are brought by Shin and col., 
(2006) showing that glycosaminoglycans may be able to regulate the expression of deubiquitination 
enzymes, since the ubiquitin specific protease (USP17) contains the putative hyaluronan/RNA 
binding motifs, suggesting that glycosaminoglycans modulate its expression. Moreover, the 
glycosaminglycan heparin inhibits casein kinase 2, an enzyme involved in phosphorylation of 
ubiquitin-conjugating enzyme, needed for its activation (Block et al., 2001). This indirect evidence 
supports the presumption that CS could have increased the expression CYP3A6 by diminishing the 
26S-proteasome. Indeed, this hypothesis is very attractive and further studies are required. 
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 On the other hand, there is compelling evidence that CS inhibits multiple proteases (Monfort et 
al., 2008). Matrix metalloproteinases (MMPs) are effectively down-regulated by CS in cultured 
chondrocytes in various studies (Wang et al., 2002; Monfort et al., 2005). Further studies are needed 
to demonstrate the effect of CS on other proteases of the ubiquitin proteasome pathway, which could 
have a role in the CYP3A6 protein stability. 
There is recent evidence that protein ubiquitination is modulated by O-GlcNAc glycosylation, 
reaction that could be a protective signal against proteasomal degradation both by modifying target 
substrates and/or by inhibiting the proteasome itself (Guinez et al., 2008; Vosseller et al., 2001). In a 
study performed by Guinez et al. (2008), glucosamine was used to increase glycosylation of proteins, 
leading to the stability of proteins against proteasomal degradation. Glucosamine (besides other 
substrates) is a source for N-acetylglucosamine (Ju et al., 2008; Kuo et al., 2008), responsible for O-
glycosylation (Medzihradszky, 2008). On the other hand, N-acetylgalactosamine is one of the 
monomers of chondroitin sulfate disaccharides (Lamari et al., 2006; Medzihradszky, 2008), 
suggesting that CS could enhance protein glycosylation; actually, N-acetylgalactosamine 
glycosylates ubiquitin ligase, reduces its activity and therefore reduces proteasome degradation (West 
et al., 2004). It is noteworthy that multiple CYP enzymes can undergo glycosylation with loss of 
activity but protection against proteolysis (Lee et al., 1998; Aguiar et al., 2005). This last mechanism 
could also be proposed to explain the post-transcriptional increase in CYP3A6 by CS.  
There is an additional recently described mechanism for the regulation of gene expression at the 
post-transcriptional level – microRNAs or miRNAs, a family of short noncoding RNA, that block 
mRNA translation or reducing mRNA stability, thus affecting protein expression (Ambros, 2004). 
In a study done by Takagi et al. (2008) it was demonstrated that miR-148a negatively regulated 
human PXR post-transcriptionally, through a recognition element 3`-UTR. Interestingly, this 
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recognition element is also present in the CYP3A4 mRNA. The expression of several CYP enzymes 
is more likely to be regulated by miRNA, such as CYP1A2, CYP1B1, CYP2B6, and CYP2S1 
(Ingelman-Sundberg et al., 2007). 
Despite growing knowledge on miRNA biology, little is known about the transcriptional 
regulation of miRNA, also on the mechanism of regulation of miRNA gene expression itself. It is 
known that miRNA are deregulated during certain conditions like cancer (Kanellopoulou et al, 2008). 
There are some data showing that the expression of miR-146 and miR-155 is associated to the 
activation and nuclear translocation of NF-κB (Taganov et al., 2006; Rai et al., 2008). Two studies 
highlighted the importance of miRNA-mediated regulation of translation in neuronal synapses 
(Ashraf et al., 2006; Schratt et al., 2006). In such context, miRNAs provide an ideal way to regulate 
rapidly and specifically protein synthesis. It has been suggested that miRNAs enhance rapid protein 
degradation (Kanellopoulou et al., 2008). There is evidence suggesting that miRNAs play an 
important role in the regulation of immune functions and inflammation (Sonkoly et al., 2008). 
Indeed, endotoxin increases the expression of numerous miRNAs as do IL-1β and IL-6 (Tili et al., 
2007; Meng et al., 2008; Perry et al., 2008).  
An alternative explanation to the post-transcriptional effect of CS on CYP3A6 expression might 
be that CS, by preventing NF-κB activation and nuclear translocation produced by turpentine-induced 
inflammatory reaction, may reduce miRNA posttranscriptional down-regulation of CYP3A6. Indeed 
further studies are needed to confirm this hypothesis. 
The observed effect of CS on the stability of CYP3A6 protein expression as a function of time 
comes to support the hypothesis that glycosylation of protein leds to its stability accordingly to 
Guinez and coll. (2008), Zhang and coll. (2003). 
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Effect of CS and the ∆di-4S, ∆di-6S and ∆di-4,6S disaccharides on CYP1A2, 
CYP3A6 and NADPH-reductase in vitro 
 
To support the results obtained with the study conducted in vivo, e.g. that CS does not affect 
activity and expression of CYP1A2 and CYP3A6 in control rabbits, several concentrations of CS and 
its disaccharides were incubated for 48 hours with hepatocytes harvested from control rabbits. The 
data obtained imply that CS or its disaccharides do not elicit a direct effect on the activity and 
expression of CYP1A2, CYP3A6 and NADPH-reductase, accordingly with the data obtained form in 
vivo studies. These results are in concordance also, with the data obtained from surveys on patients 
using dietary supplements and concurrent use of medication, since no significant drug-drug 
interactions have been reported in patients taking CS and other drugs (Wold et al, 2005).   
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VI. CONCLUSION 
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This study is the first one that shows in vivo that NF-κB nuclear translocation was prevented by 
the administration of CS, in the presence of an aseptic inflammatory reaction. Moreover CS impedes 
the increase of the concentration of nitric oxide. Seromucoids does not share a similar pattern, since 
CS does not prevent the increase in their level. 
The present study shows that CS elicits a different effect on CYP1A2 and CYP3A6, in the sense 
that CS does not affect CYP1A2 in control and in rabbits with a turpentine-induced inflammatory 
reaction. On the other hand, CS appears to reduces post-transcriptional degradation of CYP3A6, 
although the increase in protein is not accompanied by enhanced activity, suggesting that CS prevents 
the degradation of the inactive enzyme. Finally, the administration of CS did not affect the stability 
of NADPH-reductase activity and protein expression. 
In vitro studies added to this project were undertaken in the effort to answer the question whether 
chondroitin sulphate and its degradation products contribute to the effects observed in vivo. The strait 
result was that CS, 4S-, 6S and 4,6S-sulfated disaccharides of CS did not change the activity and 
expression of the two isoforms of CYP, and of NADPH. 
CYP3A4 is a very important enzyme, since in the organism more than 50% of drugs 
biotransformed are metabolized by this enzyme. The extrapolation of the effect of CS on CYP3A6 to 
human CYP3A4 suggests that the administration of CS to humans would potentially prevent the 
down-regulation of inactivated CYP3A4 under certain conditions like the presence of an 
inflammatory reaction, the presence/absence of CYP3A4 substrates, oxidative damage etc, but that 
would not affect the biotransformation of other drugs taken by polymedicated patients.  
There are other models of inflammation (like the administration of LPS) where there is a slightly 
different interplay of the circulating cytokines and where the results of this study could not be 
extrapolated entirely.  
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One observation that needs to be further explored is that the levels of CYP3A6 mRNA at 0 Days 
and 30 Days do not necessarily reflect protein expression. Additional studies are needed to determine 
which, if any, of the potential mechanisms described here, are responsible for the changes in 
CYP3A6 protein stability suggested by this study. However, mRNA measurements are generally 
good indicators for proteins that are induced rather than constitutively expressed, since the former 
ones are not likely subjected to proteasomal degradation (Robert B, 1996) 
Further studies should be done to elucidate the exacte role played by CS in the post-
transcriptional degradation of CYP3A6, and its effect on the ubiquitin-proteasome system. Also, it 
shoud be of great interest to further explore the dynamics of different proteasome subunits on 
CYP3A4, alone and in combination with selective proteasome inhibitors. 
The interesting effects of CS observed in this study does call for further exploration, while 
supporting its use in the clinic, since there are numerous clinical studies showing no severe adverse 
effects to patients who are taking this natural health product. 
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